

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [editorial.bmjopen@bmj.com](mailto:editorial.bmjopen@bmj.com)

# BMJ Open

## DIABETES PREVALENCE SURVEY OF PAKISTAN (DPS- PAK): Prevalence of type 2 Diabetes Mellitus and pre-diabetes using HbA1c: A population-based survey from Pakistan

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-025300
Article Type:	Research
Date Submitted by the Author:	14-Jul-2018
Complete List of Authors:	Aamir, Azizul Hasan; Hayatabad Medical Complex, Diabetes & Endocrinology & metabolic diseases Ul-Haq, Zia; Khyber Medical University, Institute of Public Health & Social Sciences; University of Glasgow Institute of Health and Wellbeing, Public Health Mahar, Saeed ; National Institute of Cardiovascular Diseases, Endocrinology Qureshi, Faisal; Al-Khaliq Hospital, Multan, Endocrinology Ahmad, Ibrar; Lady Reading Hospital, Endocrinology ward Jawa, Ali; Pakistan Institute of Medical Sciences, Endocrinology Sheikh, Aisha ; Aga Khan University, Endocrinology Raza, Abbas; Shaukat Khanum Memorial Cancer Hospital and Research Centre, Endocrinology Fazid, Sheraz; Khyber Medical University, Institute of Public Health & Social Sciences Jadoon, Zahid; Hayatabad Medical Complex Department of Ophthalmology, Epidemiology Ishtiaq, Osama; Shifa College of Medicine, Endocrinology Safdar, Nauman; Social and health inequalities Network, Social work Afridi, Hussain; Hayatabad Medical Complex, Department of Diabetes, Endocrinology and Metabolic Diseases Heald, Adrian; Leighton Hospital, Medicine
Keywords:	Type 2 Diabetes Mellitus, diabetes, HbA1c, Pakistan, pre-diabetes, Prevalence

SCHOLARONE™  
Manuscripts

**Title Page:****DIABETES PREVALENCE SURVEY OF PAKISTAN (DPS- PAK):  
Prevalence of type 2 Diabetes Mellitus and pre-diabetes using HbA1c: A  
population-based survey from Pakistan**

Azizul Hasan Aamir<sup>1</sup>, Zia Ul-Haq<sup>2,3</sup>, Saeed A. Mahar<sup>4</sup>, Faisal Masood Qureshi<sup>5</sup>, Ibrar Ahmad<sup>6</sup>,  
Ali Jawa<sup>7</sup>, Aisha Sheikh<sup>8</sup>, Abbas Raza<sup>9</sup>, Sheraz Fazid<sup>2</sup>, Zahid Jadoon<sup>10</sup>, Osama Ishtiaq<sup>11</sup>,  
Nauman Safdar<sup>12</sup>, Hussain Afridi<sup>1</sup>, Adrian H. Heald<sup>13</sup>

<sup>1</sup> Department of Diabetes, Endocrinology and Metabolic Diseases, Hayatabad Medical Complex, Peshawar, Khyber Pakhtunkhwa, Pakistan

<sup>2</sup> Institute of Public Health & Social Sciences, Khyber Medical University, Peshawar, KP, Pakistan

<sup>3</sup> Institute of Health and Wellbeing, University of Glasgow, Glasgow G12 8RZ, UK

<sup>4</sup> National Institute of cardiovascular diseases, Karachi

<sup>5</sup> Al-Khaliq Hospital, Multan.

<sup>6</sup> Lady Reading hospital, Peshawar.

<sup>7</sup> Pakistan Institute of medical sciences, Islamabad.

<sup>8</sup> Aga Khan University Hospital, Karachi.

<sup>9</sup> Shaukat Khanum Hospital, Lahore.

<sup>10</sup> Hayatabad Medical Complex, Peshawar.

<sup>11</sup> Shifa International Hospital, Islamabad.

<sup>12</sup> Social and Health Inequalities Network, Islamabad.

<sup>13</sup> The school of medicine and Manchester academic sciences centre, University of Manchester, Manchester, United Kingdom.

1. Azizul Hasan Aamir: [drahaamir@gmail.com](mailto:drahaamir@gmail.com), MBBS, MRCP, FRCP, FACE
2. Zia Ul Haq: [drzia@kmu.edu.pk](mailto:drzia@kmu.edu.pk), MBBS, MPH, PhD
3. Saeed A. Mahar: [saeedamahar@yahoo.com](mailto:saeedamahar@yahoo.com). FRCP
4. Faisal Qureshi: [f-qureshi@hotmail.com](mailto:f-qureshi@hotmail.com). FACE
5. Ibrar Ahmed: [ibrar2127@hotmail.com](mailto:ibrar2127@hotmail.com). FCPS
6. Ali Jawa: [alijawa@gmail.com](mailto:alijawa@gmail.com). FACE
7. Aisha Shiekh: [aisha.sheikh@aku.edu](mailto:aisha.sheikh@aku.edu). FCPS
8. Abbas Raza: [sabbasraza@hotmail.com](mailto:sabbasraza@hotmail.com). FACE
9. Osama Ishtiaq: [docosama@gmail.com](mailto:docosama@gmail.com). FCPS
10. Sheraz Fazid: [sherazvs@gmail.com](mailto:sherazvs@gmail.com) PhD Scholar, MPH
11. Zahid Jadoon: [zahid@pico.org.pk](mailto:zahid@pico.org.pk). MSc
12. Nauman Safdar: [safdar.nauman@gmail.com](mailto:safdar.nauman@gmail.com). PhD
13. Hussain Afridi: [mhussainafd@gmail.com](mailto:mhussainafd@gmail.com). FCPS
14. Adrian H. Heald: [adrian.heald@manchester.ac.uk](mailto:adrian.heald@manchester.ac.uk). FRCP

1  
2  
3 Correspondence to:  
4

5 Prof.Aziz ul Hasan Aamir

6 Head of the Department of Diabetes, Endocrinology and Metabolic Diseases

7 Hayatabad Medical Complex

8 Phase 5, Hayatabad, Peshawar, Pakistan

9 e-mail:drahaamir@gmail.com

10 Tel: +92 -91- 921-7794  
11  
12  
13

14 Word count (abstract) 259

15 Word count (main text) 3188

16 Figures 01

17 Tables 03  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

### Objectives

We conducted a Pakistan-wide community-based survey on the prevalence of type-2 diabetes using HbA1c. The only previous national survey was conducted in 1999 using Oral glucose tolerance test (OGTT).

### Design, settings and participants

Multi-staged stratified cluster sampling was used for the representative selection of person aged  $\geq 20$  years, residing in 378 sampled clusters of 16 randomly selected districts. Eligible participants were called to the nearby field clinic for HbA1c analyses. OGTT was conducted on a subsample of the participants. Overall and stratified prevalence of type-2 diabetes and its association with risk factors were estimated using logistic regression models through STATA-14.

### Main outcome measures

Prevalence of pre-diabetes and type 2 diabetes

### Results

Of 18,856 eligible participants the prevalence of pre-diabetes was 10.91% (95% CI 10.46, 11.36,  $n=2,057$ ) and type-2 diabetes was 16.98% (95%CI 16.44, 17.51,  $n=3,201$ ). Overall, the mean HbA1c level was 5.62% (SD 1.96), and among newly diagnosed was 8.56% (SD 2.08). The prevalence was highest in age 51-60 years (26.03%,  $p<0.001$ ), no formal education (17.66%,  $p<0.001$ ), class-3 obese (35.09%,  $p<0.001$ ), family history (31.29%,  $p<0.001$ ) and female (17.80%,  $p=0.009$ ). On multivariate analysis, there was a significant dose-response relationship of type-2 diabetes with age, BMI, central obesity, family history, and hypertension and the inverse relationship with education. On a subsample ( $n=1,027$ ), summary statistics for diagnosis of diabetes on HbA1c showed a sensitivity of 84.7%, specificity of 87.2%, and ROC area 0.86, compared to OGTT.

### Conclusions

The prevalence of type-2 diabetes and pre-diabetes is higher than what was reported before in Pakistan and demands public health emergency against this deadly disease.

### Key words (mesh terms):

Type 2 Diabetes Mellitus, diabetes, Prevalence, HbA1c, OGTT, obesity, pre-diabetes, Pakistan

### Strength and limitations of this study

- This is the 2nd national prevalence study of type-2 diabetes mellitus from Pakistan conducted after 20 years and the first community based national study to use HbA1c as the diagnostic tool with a large sample of 18,856 subjects.
- This study presents estimates that are more valid and scientifically sound than the available evidence on type-2 diabetes mellitus prevalence from a country (Pakistan) that boasts a population of 220 million.
- Our findings have the potential to influence policy in developing countries and induce a shift towards the prevention and control of Non-communicable diseases.
- Limitation includes the lesser number (n=1,027) of 2 hours Oral Glucose Tolerance Test for comparisons with HbA1c (n=18,856).

## Background

Type 2 Diabetes Mellitus is one of the most common public health issues and its incidence is on the rise particularly in the middle and low-income countries[1]. When associated with complications, type-2 diabetes can have a profound impact on the person with consequences on the society as a whole. It was thought to be the disease of the affluent and mostly in the urban areas but due to urbanization and the sedentary lifestyle it has affected developing nations, including Pakistan[2].

Pakistan is a South Asian country with an area of 796,095 km<sup>2</sup> and a population of 207.7 million people[3]. In terms of population, Pakistan is the 6<sup>th</sup> most populous country and is the 36<sup>th</sup> largest country in the world. The only previous national diabetes survey in Pakistan back in 1999 (published in 2007), reported the prevalence of type-2 diabetes as 11% using Oral Glucose Tolerance Test (OGTT) [4 5]. Part of the same survey separately reported the prevalence of type-2 diabetes in different provinces of Pakistan [6-8]. The International Diabetes Federation (IDF) reported in its atlas 20 the prevalence for Pakistan to be 6.8%, aged 20-79[9], but the health care professionals always believed this to be an underestimate as it is in majority based on OGTT only, 2 decades old national survey and there are conflicting findings with prevalence ranges from 7.2%-19.21% done in different regions of the country [5].

The American Diabetes Association (ADA) criteria for the diagnosis of diabetes require either fasting plasma glucose (FPG) or 75gm OGTT which is time-consuming, requires fasting and may not be reproducible as affected by acute glucose changes and lifestyle interventions[10 11]. In 2009, the International Expert committee on diabetes proposed new diagnostic criteria based on Glycated Haemoglobin (HbA1c), which captures chronic glucose exposure[12]. The proposed diagnostic threshold of 6.5% (48mmol/mol) was based on retinopathy risk at different levels of HbA1c as was the case with FPG and OGTT. This report was followed by a recommendation from the ADA. An HbA1c level of 6.5% (48mmol/mol) was agreed to be a diagnostic cut-off for the diagnoses of diabetes[13].

In summary, there is only one previous national level type-2 diabetes survey conducted in 1999 with sample size of 5433 using OGTT. In this study we investigated the prevalence of type-2 diabetes (using the HbA1c test) and its distribution across gender, age, rural and urban, education, Body Mass Index (BMI) WHO and Asian cut-offs, family history, smoking, and blood pressure among a large sample across Pakistan, aged 20 years and above. A sub sample was tested to explore the diagnostic summary statistics for diagnosis of type-2 diabetes on HbA1c, compared to 2 hours OGTT.

## Methods

The Department of Diabetes, Endocrine and Metabolic Diseases, Hayatabad and Department of Health, Government of Khyber Pakhtunkhwa, Pakistan with technical support from Institute of Public Health, Khyber Medical University Peshawar Pakistan, University of Manchester UK and Pakistan Endocrine Society have conducted a nationwide cross-sectional study for the prevalence of type-2 diabetes in April 2017 and completed in November 2017. Three teams under the supervision of epidemiologists were formulated and trained to take basic demographic data on the sample to be screened. These national samples were selected based on a stratified two-stage cluster design, including all metropolitan cities of Pakistan and randomly selected districts (both rural and urban settings) within each province. The sample included districts from central and south of Punjab province (Lahore, Multan, Bahawalpur, Rahim Yar Khan), interior Sindh (Larkana, Dadoo, Sukkur), central Sindh (Karachi), northern Khyber Pakhtunkhwa (KP) (Haripur), central (Peshawar) and southern KP province (Karak), Baluchistan province (Quetta), capital territory (Rawalpindi-Islamabad), Azad Jammu Kashmir (Muzaffarabad), Frontier region Peshawar and the Khyber Agency in Federal Administered Tribal Area (FATA).

### Sample size and sampling methodology:

The sample size was estimated for the provinces of the country based on recent census results. The sample size was estimated based on an expected prevalence of 12% with 20% precision and a design effect of 2[6]. For 95% confidence interval and an additional of 32% for non-responders, keeping in view an exclusion rate due to an expected high prevalence of anaemia, the sample size was 4407 approximated to 4500 in order to have 50 subjects from each cluster. The four provinces were included and Federal territory; AJK and FATA were considered as one province for the survey purpose because of their small size of the population. The number of eligible subjects was  $4500 \times 5 = 22500$ .

Three districts were randomly selected from each province and the sample size was equally divided on these districts. Fifteen hundred subjects (30 clusters, 50 subjects per cluster) were examined in each district. The sample was proportionately divided amongst urban and rural area. Probability proportionate to size (PPS) method was used to select clusters from villages in the rural settings of the district. In urban settings, clusters were selected from charges and circles (defined in the national census) using PPS method.

Maps were obtained from the census office of selected villages/charges/circles (V/C/C). Maps of each V/C/C was divided into equal segments such that each segment has approximately 50 persons 20 years and above. One segment was randomly selected and every house within the segment was included. All persons 20 and above living in that house were examined until 50 number is reached. Any person who was absent on the day of survey till evening time was terminally ill, or fitted into excluding criteria or who refused were marked as non-responders.



1  
2  
3 The ethical approval was granted from Khyber Medical University ethical board (DIR/KMU-  
4 EB/SP/000395). Conditions that may affect HbA1C including anaemic subjects with  
5 haemoglobin less than 12gm/dl in women and less than 14 gm/dl in men, self-reported renal and  
6 hepatic dysfunction, recent blood transfusion, and use of erythropoietin anyone aged below 20  
7 years or refused to participate were excluded. Face to face interviews was conducted at  
8 participant's homes to collect information on demographics (including age, gender, residential  
9 area, formal education, family history of diabetes, and smoking status) in the paper questionnaire  
10 in local languages. Eligible participants were called to a central point established in hujra (local  
11 public gathering place) where their Haemoglobin was tested using mission plus Haemoglobin  
12 meter (reflectance photometer technique) Acon Laboratories, Inc., San Diego (coefficient of  
13 variance CV:3%). Blood pressure was measured using an automated digital blood pressure  
14 monitor Konfort Model AS-351 in the lying position with the average of three readings was  
15 recorded. Weight in kilograms and height in meters was recorded and used to calculate Body  
16 Mass Index.  
17  
18  
19  
20  
21  
22

23 Diabetes status was assessed for HbA1c on blood samples using National Glycohemoglobin  
24 Standardization Program (NGSP) certified FIA 8000 immunoassay analyser (lateral flow  
25 chromatography colloidal gold) traceable to diabetes control and complication trial (DCCT)  
26 reference method(CV: 3-5%). To compare the results from HbA1c, 2 hours OGTT was  
27 conducted on a random sample of participants from all clusters (n=1,027) in the specified  
28 standard laboratory using Cobas C311 Roche Diagnostics. Participants were given vouchers for  
29 free OGTT test within 7 days in a nearby laboratory using Cobas C311 Roche Diagnostics.  
30  
31  
32

### 33 Definitions

34 Age was categorised into six groups: 20-30, 31-40, 41-50, 51-60 and 61 and above years. The  
35 residential area was classified as urban and rural based on local government criteria. Formal  
36 education status was self-reported was categorized as no formal education, primary, secondary  
37 and graduation/post graduation. BMI was categorised on WHO criteria into underweight (<18.5  
38 kg/m<sup>2</sup>), normal weight (18.5-24.9 kg/m<sup>2</sup>), overweight (25-29.9 kg/m<sup>2</sup>), class I obese (30-34.9  
39 kg/m<sup>2</sup>), class II obese (35-39.9 kg/m<sup>2</sup>), and class III obese (>40 kg/m<sup>2</sup>)(World Health  
40 Organization., 1995). Waist Circumference (WC) was categorized into normal-weight (0-93.99),  
41 overweight (94-102) and obese (102 & above).Waist to hip ratio (WHR) was categorized into  
42 normal-weight (0-0.89), overweight (0.90-0.99) and obese (1 & above)[14].The family history of  
43 diabetes was categorised to negative or positive on participant's self-reporting based on  
44 physician's diagnoses. Smoking status was categorized as never, ex or current smoker. Systolic  
45 and diastolic blood pressure was measured using standard procedure and was hypertension was  
46 based on blood pressure measurement of  $\geq 140/90$  mmHg or anti-hypertensive medication.  
47 Patients were considered as known type-2 diabetes on the basis of self-reporting and or being on  
48 dietary or exercise advice, oral anti-diabetic medications or insulin. This self-reported group of  
49 patients could either be on individual medications or on different drug combinations or diet and  
50 exercise therapy.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 Type 2 diabetes was diagnosed based on HbA1c results keeping the WHO levels of non diabetic  
5 (<5.69 % DCCT aligned/38 mmol/mol IFFC units), pre-diabetes (5.7-6.49% DCCT aligned/  
6 39-47mmol/mol IFFC units), diabetes ( $\geq 6.5$  % DCCT aligned /48 mmol/mol IFFC units). For  
7 univariate and multivariate logistic regression models, diabetes was dichotomized to No (0;  
8 HbA1C level <6.5) and Yes (1; HbA1C level  $\geq 6.5$ ).  
9  
10

### 11 Statistical Analyses

12 Differences in the characteristics of participants by diabetes category were analysed using the  $\chi^2$   
13 test for categorical data and ANOVA for continuous data. We examined the association between  
14 diabetes and risk factors i.e., age, gender, residence area, education, BMI, family history of  
15 diabetes, smoking, systolic and diastolic blood pressure, using univariate and multivariate  
16 logistic regression models. Taking OGTT as the standard on a sub subsample, the diagnostic  
17 summary statistics (sensitivity, specificity, ROC area, positive and negative predictive value) for  
18 diagnosis of diabetes on HbA1c was measured. All statistical analyses were performed using  
19 Stata version 14 (StataCorp, College Station, Texas). Statistical significance was defined as  
20  $p < 0.05$  and analysis were adjusted for the cluster design.  
21  
22  
23  
24  
25  
26

### 27 **Patient and Public Involvement statement:**

28  
29 Patients were not involved in this study.  
30  
31  
32  
33

### 34 **Results**

35 Of the 22,500 participants, 3,644 (16%) were anaemic and therefore excluded from the study.  
36 Out of the remaining, 18,856 participants aged 20 and above, were actually examined from 378  
37 clusters of which 216 were rural generating a response rate of 84%. The mean age was 45.23  
38 years (standard deviation [SD] 13.97 years), 10,116 (53.55%) were men, 4,148 (21.96%) were  
39 hypertensive and those with higher blood pressure were advised to check their blood pressure by  
40 visiting their doctors, 13,834 (73.24%) had no formal education, and 1,209 (6.40) had  
41 graduation, and 6,010 (31.81%) had family history of type-2 diabetes. Overall on WHO cut-off  
42 345 (1.83%) were underweight, 6,839 (36.20%) normal-weight, 8,038 (42.55%) overweight,  
43 2,864 (15.16%) class I obese, 633 (3.35%) class II obese, and 172 (0.91%) class III obese. On  
44 WC cut-off (n=12865) 1,142 (13.32%) were normal-weight, 357 (15.40%) were overweight and  
45 543 (27.51%) were obese. On central obesity cut-off (WHR, n=12865) 658 (15.41%) were  
46 normal weight, 1171 (15.68%) were overweight and 213 (18.90%) were obese. Mean systolic  
47 blood pressure was 126.30mmHg (SD 14.2) and diastolic blood pressure was 83.24mmHg (SD  
48 10.2).  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Overall, 3,201 subjects (16.98% (95%CI 16.44, 17.51) had type-2 diabetes based on HbA1c  
4 screening. Pre-diabetes was present in 2,057 subjects 10.91% (95% CI 10.46, 11.36).The mean  
5 HbA1c level of the entire cohort (n=18856) was 5.62% (SD 1.96), among known type-2 diabetes  
6 (n=2179) had 8.68% (SD 2.70) and newly diagnosed type-2 diabetes (n=1577) had 8.56%  
7 (SD2.08). The prevalence of diabetes differed significantly by age, education, BMI, WC, WHR,  
8 family history, and blood pressure (Table 1) (Figure 1). The prevalence of diabetes was highest  
9 in age 51-60 years (26.03%, p<0.001), no formal education (17.73%, p<0.001), class 3 obese  
10 (32.19%, p<0.001), and with a positive family history of diabetes (31.34%, p<0.001) (Figure 1).  
11 There were also statistically significant differences in diabetes prevalence by gender (female  
12 17.85%, p=0.01), rural/urban (rural 19.09%, p<0.001) and that smoking status (p=0.008).  
13  
14  
15  
16  
17

18 On univariate logistic regression analysis, there was a significant association between age,  
19 gender, education, BMI category, family history, blood pressure and diabetes (p<0.005)(Table  
20 2). On multivariate logistic regression, there was significantly higher risk of diabetes with age  
21 (adjusted Odds Ratio [OR] 2.03, 95% CI 3.39, 4.87 and 4.93, p< 0.001, aged 31-40 years, 41-50  
22 years, 51-60 years and 61 years and above respectively, compared to age 20-30 years), BMI  
23 (adjusted OR 1.54, 95% CI 2.13, 2.44,p-value <0.001 for class 1, class II and class III obese  
24 respectively, compared to normal weight) with evidence of dose-response relationship. Similarly,  
25 there was a significantly higher risk of diabetes with lower educational attainment (adjusted OR  
26 1.83, 95% CI 1.39, 1.57, no formal education, primary and secondary education respectively,  
27 compared to graduates). There was a significantly higher risk of diabetes in people with a  
28 positive family history (adjusted OR 3.94, 95% CI 3.6, 4.3 p< 0.001), than with no family history  
29 of diabetes. There was no significant association with smoking and rural/urban area.  
30  
31  
32  
33  
34

35 Among 1,029 participants who were tested for 2hrs OGTT, in addition to HBA1C, the mean 2  
36 hours OGTT was 200.26 (SD 91.7), and the median was 178 (inter-quartile range 100). Taking  
37 the OGTT as the gold standard, HbA1c recommended cut-off for diabetes showed a sensitivity  
38 of 84.7% (95% CI 80.8, 88) and Specificity of 87.2% (95% CI 84.3, 89.8%), ROC area 0.86  
39 (95% CI 0.84, 0.88), positive predictive value 81.9% (95% CI 77.9, 85.4), and negative  
40 predictive value 89.3 (86.5, 91.6) (Table 3).  
41  
42  
43  
44  
45

#### 46 **Discussion:**

47 This is the first community based national study done in the region based on HbA1c and with the  
48 eligible 18,856 subjects from the country as sample size makes this study largest to date from  
49 Pakistan. The prevalence of type-2 diabetes all across Pakistan was 16.98% (95%CI 16.44,  
50 17.51) and pre-diabetes was 10.91% (95% CI 10.46, 11.36). This is higher than found in the only  
51 previous national survey conducted in1999 (n=5433) using OGTT. There was a significantly  
52 higher risk of type-2 diabetes with increasing systolic blood pressure, age, BMI, WC, WHR with  
53 evidence of a dose-response relationship. Similarly, there was a significant inverse relationship  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 of type-2 diabetes with the level of formal education. The risk of diabetes increases 2.68 times  
4 with a prior family history. The hba1c level had good sensitivity and specificity level for the  
5 diagnoses of type-2 diabetes compared to a 2-hour OGTT level and is feasible in community  
6 settings for screening purposes.  
7  
8  
9

10  
11 Previous national prevalence study used OGTT where almost 80% of the subjects were women  
12 as conducted in the morning time (4). In contrast, our study screening was done all through the  
13 day due to which working men had equal opportunity to be part of the sample and constituted  
14 50% of the study population. OGTT was the gold standard for the diagnosis but because of the  
15 length of time which is required for the test and the fact that person had to be fasting; making it  
16 very difficult to do a standard test without errors. Also, high temperatures in South Asia make it  
17 difficult to carry out while keeping the sample steady for transportation to the laboratory. To  
18 minimize the effect of temperature and transportation errors on HbA1c all tests were conducted  
19 in the field.  
20  
21  
22

23  
24 Recently a study carried out in 15 states of India showed the prevalence of type-2 diabetes  
25 ranging between 4%-13.6% and showed variation due to age, male sex, obesity, family history as  
26 independent risk factors using capillary FBG for diagnosis [15]. Capillary blood sample for  
27 epidemiological studies is not an ideal test but the authors acknowledged the logistic hindrance  
28 in carrying out venous sample test in the field. High prevalence in another Indian study was  
29 reported ranging from 12.1-14% for diabetes using OGTT on a sample size of 11,216  
30 subjects[16].  
31  
32  
33

34  
35 A study conducted in Bangladesh was based on capillary fasting level prevalence type-2 diabetes  
36 in the range of 4.3% in a rural setting[17]. Risk factors were positive family history for diabetes,  
37 age, high BMI and low socio-economic status, similar to our study. Although these are  
38 geographically distant areas, the risk factors showed commonality in both studies, which  
39 suggests these risk factors as an important tool for mass screening[18].  
40  
41

42  
43 The age sex-standardized prevalence of type-2 diabetes for Sri Lankans was 10.3% based on  
44 OGTT[19]. The risk factors were almost the same as seen in our study. The investigators found  
45 dysglycaemia in almost 21.8% participants and predicted that this would lead to higher  
46 prevalence in the years to come. Another study from Sri Lanka indicated a prevalence of 14.2%  
47 basis of FBG[20]. FBG as well as, OGTT blood glucose levels, may not be reproducible in an  
48 epidemiological survey if the individual is changing lifestyle with diet and exercise. With HbA1c  
49 used in our study makes our study more scientific, addressing issues pertaining to sampling  
50 errors in the local environment.  
51  
52  
53

54  
55 The Asian population is known to have a significantly higher risk of developing diabetes and its  
56 related complications as predicted by IDF projections [1]. It makes it very important from a  
57  
58  
59

1  
2  
3 public health point of view to identify high-risk individuals at an early stage. The HbA1c has  
4 been used successfully in community settings[21]. National health survey New Zealand in 2008-  
5 9 used HbA1c to identify high-risk individuals with diabetes and pre-diabetes[22]. A study in  
6 Japan revealed that a combination of tests including FBG and HbA1c yields more diabetes cases  
7 compared to any of these tests alone[23].  
8  
9

10  
11 WHO experts have accepted HbA1c as a diagnostic tool provided quality assurance tests are in  
12 place and there are no conditions present which precludes its accurate measurement. New  
13 Zealand society for the study of diabetes and Australian diabetes Society has already endorsed  
14 HbA1c as a test for the diagnosis of diabetes[24 25]. Recently prevalence study done in Korea  
15 concluded that FBG level results in underestimation of diabetes and pre-diabetes[26]. This study  
16 suggested the use of standardized HbA1c as a diagnostic tool for diagnosis of type-2 diabetes.  
17  
18

19  
20 Our study had the strength that we carried out both HbA1c and OGTT on a subsample. We found  
21 that HbA1c level had a good sensitivity and specificity level for diagnoses of diabetes compared  
22 to 2-hrs OGTT level. HbA1C has the advantage of being a simple test and less time to consume,  
23 making it an ideal test for community surveys in our populations. In Pakistan, as there is no  
24 effective and practical primary care (General Practice) concept and hence most of the population  
25 is not screened at primary level and person present to tertiary care with florid complications. This  
26 demands a test which can be done in the community setting without any preparations like HbA1c  
27 for screening purpose. There will always be the argument about the cost of the test and whether  
28 this to be used for screening purposes, however disadvantaged population need to be accessed to  
29 improve diagnosis and care of diabetes[27], needless to say, early diagnosis will also reduce  
30 diabetes-related complications.  
31  
32  
33  
34  
35

36 The central Government of Pakistan has developed and agreed on Non- Communicable Diseases  
37 (NCD) National Action Plan including diabetes, however, it was never implemented. After the  
38 18<sup>th</sup> Amendment in the constitution of Pakistan in 2010, provinces are responsible for making  
39 and implementing their own health policies and the role of central Government is limited to  
40 coordination among the different provinces[28]. There is a dire need that based on the agreed  
41 NCD National Action Plan each province should build their capacity for implementing it at both  
42 primary and secondary level. Pakistan is a signatory to the Sustainable Development Goal 2030  
43 and under which actions, like increasing access to universal health coverage, increasing coverage  
44 of health insurance program and adopting family medicine approach, will not only be major  
45 steps towards prevention and control of diabetes but all NCDs.  
46  
47  
48  
49

### 50 **Conclusions:**

51 This second national diabetes prevalence study conducted after 20 years and the first one in the  
52 region using HbA1c identified a huge population of type-2 diabetes and pre-diabetes group.  
53 Those who are obese, with no formal education, older, family history of diabetes and  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 hypertensive merit close attention and timely intervention. HbA1c is an applicable test in  
4 community settings in developing countries and it has a good correlation with 2 hours OGTT.  
5  
6  
7  
8  
9  
10

11  
12 **Acknowledgements** Khyber Pakhtunkhwa Government of Pakistan and field staff for supporting  
13 survey. Pakistan Endocrine Society for technical and logistic support in this survey.  
14 Institute of public health Khyber medical university for statistical support. The University of  
15 Manchester for help in data analysis and reviewing the manuscript.  
16

17  
18 **Contributors** AHA, ZUH conceived the study. AHA, SM, FQ, AS, AJ, OI, AR, IA, HA  
19 collected the data. ZUH, AHA, SF, AH, conducted the analysis and wrote the manuscript. All  
20 authors reviewed the manuscript. AHA and ZUH contributed equally.  
21

22  
23 **Funding Statement** This research received no specific grant from any funding agency in the  
24 public, commercial or not-for-profit sectors.  
25

26 **Competing interest** All authors have no competing interest to declare.  
27

28 **Patient Consent** Written informed consent granted. The data is fully anonymised and neither the  
29 patient nor anyone else could identify the patient.  
30

31  
32 **Ethical approval** The ethical approval was granted from the Khyber Medical University ethical  
33 board (DIR/KMU-EB/SP/000395).  
34

35 **Data sharing statement** No additional data are available  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**References:**

1. Cho NH, Shaw JE, Karuranga S, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. *Diabetes Res Clin Pract* 2018; 138: 271-281.
2. Roglic G, Unwin N Fau - Bennett PH, Bennett Ph Fau - Mathers C, et al. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. *Diabetes Care* 2015; 0149-5992.
3. Provisional summary results of 6th population and housing census-2017. Secondary Provisional summary results of 6th population and housing census-2017; <http://www.pbs.gov.pk/content/provisional-summary-results-6th-population-and-housing-census-2017-0> (accessed July 2018).
4. Shera AS, Jawad F Fau - Maqsood A. Prevalence of diabetes in Pakistan. *Diabetes Res Clin Prac* 2007;76(2):219-22
5. Meo SA, Zia I, Bukhari IA, et al. Type 2 diabetes mellitus in Pakistan: Current prevalence and future forecast. *JPMA* 2016; 66 (12):1637-42.
6. Shera AS, Rafique G Fau - Khwaja IA, Khwaja Ia Fau - Baqai S, et al. Pakistan National Diabetes Survey prevalence of glucose intolerance and associated factors in North West at Frontier Province (NWFP) of Pakistan. *J Pak Med Assoc* 1999; 49 (9): 206-11.
7. Shera AS, Rafique G Fau - Khawaja IA, Khawaja Ia Fau - Baqai S, et al. Pakistan National Diabetes Survey: prevalence of glucose intolerance and associated factors in Baluchistan province. *Diab Res Clin Pra* 1999; 49-58.
8. Shera AS, Rafique G Fau - Khwaja IA, Khwaja Ia Fau - Ara J, et al. Pakistan national diabetes survey: prevalence of glucose intolerance and associated factors in Shikarpur, Sindh Province. *Diab Med* 1995; 12 (12): 1116-21.
9. Whiting DR, Guariguata L, Weil C, et al. IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. *Diab Res Clin Pra* 2011; 94(3):311-21.
10. Diagnosis and classification of diabetes mellitus. *Diabetes Care* 2014; 37: S81–S90.
11. Klein BE. Overview of epidemiologic studies of diabetic retinopathy. *Opth Epid* 2007; 14 (4)-179-83.
12. The International Expert C. International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes. *Diabetes Care* 2009;32(7):1327-34.

13. American Diabetes A. Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 2010;33(Suppl 1): S62-S69.
14. Ahmad N, Adam SIM, Nawi AM, et al. Abdominal Obesity Indicators: Waist Circumference or Waist-to-hip Ratio in Malaysian Adults Population. *Int J of Prev Med* 2016;7:82.
15. Anjana RM, Deepa M, Pradeepa R, et al. Prevalence of diabetes and prediabetes in 15 states of India: results from the ICMR-INDIAB population-based cross-sectional study. *Lanc Diab End* 2017; 5(8):585-96.
16. Ramachandran A, Snehalatha C Fau - Kapur A, Kapur A Fau - Vijay V, et al. High prevalence of diabetes and impaired glucose tolerance in India: National Urban Diabetes Survey. *Diabetologia* 2001;44(9):1094-101.
17. Sayeed MA, Mahtab H Fau - Akter Khanam P, Akter Khanam P Fau - Abdul Latif Z, et al. Diabetes and impaired fasting glycemia in a rural population of Bangladesh. *Diabetes Care*; 2003; 26(4):1034-9.
18. McKeigue PM, Marmot Mg Fau - Syndercombe Court YD, Syndercombe Court Yd Fau - Cottier DE, et al. Diabetes, hyperinsulinaemia, and coronary risk factors in Bangladeshis in east London. *Br Heart J* 1988; 60(5) 390-96.
19. Katulanda P, Constantine Gr Fau - Mahesh JG, Mahesh Jg Fau - Sheriff R, et al. Prevalence and projections of diabetes and pre-diabetes in adults in Sri Lanka--Sri Lanka Diabetes, Cardiovascular Study (SLDCS). *Diabet Med* 2008; 25(9) 1062-9.
20. Wijewardene K, Mohideen Mr Fau - Mendis S, Mendis S Fau - Fernando DS, et al. Prevalence of hypertension, diabetes and obesity: baseline findings of a population based survey in four provinces in Sri Lanka. *Ceylon Med J* 2005; 50(2) 62-70.
21. Grant T, Soriano Y Fau - Marantz PR, Marantz Pr Fau - Nelson I, et al. Community-based screening for cardiovascular disease and diabetes using HbA1c. *Am J Prev Med* 2004; 26(4) 271-5.
22. Coppell KJ, Mann Ji Fau - Williams SM, Williams Sm Fau - Jo E, et al. Prevalence of diagnosed and undiagnosed diabetes and prediabetes in New Zealand: findings from the 2008/09 Adult Nutrition Survey. *N Z Med J* 2013; 126(1370):23-42.
23. Takahashi Y, Noda M Fau - Tsugane S, Tsugane S Fau - Kuzuya T, et al. Prevalence of diabetes estimated by plasma glucose criteria combined with standardized measurement of HbA1c among health checkup participants on Miyako Island, Japan. *Diabetes Care* 2000; 23(8): 1092-6.
24. d'Emden MC, Shaw Je Fau - Colman PG, Colman Pg Fau - Colagiuri S, et al. The role of HbA1c in the diagnosis of diabetes mellitus in Australia. *Med J Aust* 2012; 197(4):220-1.
25. Braatvedt GD, Cundy T Fau - Crooke M, Crooke M Fau - Florkowski C, et al. Understanding the new HbA1c units for the diagnosis of Type 2 diabetes. *N Z Med J* 2012; 125 (1362) 70-80.



1  
2  
3 26. Jeon JY, Ko S-H, Kwon H-S, et al. Prevalence of Diabetes and Prediabetes according to  
4 Fasting Plasma Glucose and HbA1c. *Diabetes Metabol J* 2013;37(5):349-57.  
5

6 27. Degeling C, Rock M Fau - Rogers WA, Rogers WA. Testing relationships: ethical arguments  
7 for screening for type 2 diabetes mellitus with HbA1C. *J Med Ethics* 2012; 38(3): 180-3.  
8

9 28. Nishtar S, Boerma T Fau - Amjad S, Amjad S Fau - Alam AY, et al. Pakistan's health  
10 system: performance and prospects after the 18th Constitutional Amendment. *Lancet* 2013;  
11 381(9884):2193-206.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Table 1 Characteristics of the participants by diabetes categories (n=18,856)

	Non-Diabetic N (%)	Pre-Diabetic N (%)	Diabetic N (%)	P-value
	13,598 (72.11)	2,057 (10.91)	3,201 (16.98)	
<b>Age (years)</b>				
20-30	2,772 (20.37)	218 (10.60)	176 (5.52)	<0.001
31-40	3,503 (25.74)	425 (20.66)	511 (16.01)	
41-50	3,802 (27.94)	654 (31.79)	1,033 (32.37)	
51-60	1,955 (14.37)	412 (20.03)	833 (26.10)	
61 & above	1,576 (11.58)	348 (16.92)	638 (19.99)	
<b>Gender</b>				
Male	7363 (54.15)	1099 (53.43)	1638 (51.17)	0.010
Female	6235 (45.85)	958 (46.57)	1563 (48.83)	
<b>Education</b>				
No formal education	9,853 (72.41)	1516 (73.70)	2,439 (76.43)	<0.001
Primary	1936 (14.23)	354 (17.21)	452 (14.16)	
Secondary	818 (6.01)	99 (4.81)	184 (5.77)	
Graduation	1001 (7.36)	88 (4.28)	116 (3.64)	
<b>Area</b>				
Urban	9,117 (67.00)	1,213 (58.97)	1,932 (60.55)	<0.001
Rural	4,491 (33.00)	844 (41.03)	1,259 (39.45)	
<b>Family History</b>				
Negative	10325 (75.93)	1210 (58.82)	1320 (41.24)	<0.001
Positive	3273 (24.07)	847 (41.18)	1881 (58.76)	
<b>Smoking</b>				
Never	12682 (93.26)	1893 (92.03)	2937 (91.75)	0.008
Ex-Smoker	275 (2.02)	49 (2.38)	91 (2.84)	
Current smoker	641 (4.71)	115 (5.59)	173 (5.40)	
<b>Systolic BP (mean ±SD)</b>	124.98	128.17	130.77	0.020
<b>Diastolic BP (mean ±SD)</b>	82.75	84.13	84.84	0.006
<b>BMI</b>				
Underweight (<18.5)	279 (2.05)	31 (1.51)	35 (1.09)	
Normal (18.5-<25)	5137 (37.78)	668 (32.47)	1019 (31.83)	<0.001
Overweight (25-<30)	5884 (43.27)	850 (41.32)	1288 (40.24)	
Obese1 (30-<35)	1844 (13.56)	396 (19.25)	621 (19.40)	
Obese 2 (35-<40)	372 (2.74)	83 (4.04)	178 (5.56)	
Obese 3 (≥40)	82 (0.60)	29 (1.41)	60 (1.87)	
<b>Waist circumference *</b>				
Normal Weight	6,787 (70.88)	645 (51.68)	1,142 (55.93)	
Over weight	1,676 (17.50)	285 (22.84)	357 (17.48)	<0.001
Obese	1,113 (11.62)	318 (25.48)	543 (26.59)	
<b>Waist to Hip ratio *</b>				
Normal Weight	3,219 (33.62)	394 (31.57)	658 (32.22)	
Over weight	5,528 (57.73)	768 (61.54)	1,171 (57.35)	
Obese	828 (8.65)	86 (6.89)	213 (10.43)	0.002

\* n for Waist circumference & waist to hip ratio is 12865

Table 2 Logistic regression analysis of the participant characteristics associated with having diabetes (HbA1C  $\geq$ 6.5 % DCCT aligned /48 mmol/mol IFCC units) (n=18,856)

	Univariate OR (95% CI)	P-value	Multivariate OR (95% CI)	P-value
<b>Age</b>				
20-30	1		1	
31-40	2.21 (1.8, 2.6)	<0.001	2.03 (1.7, 2.4)	<0.001
41-50	3.93 (3.3,4.6)	<0.001	3.39 (2.9, 4.0)	<0.001
51-60	5.97 (5.0, 7.1)	<0.001	4.87 (4.1, 5.8)	<0.001
61 & above	5.63 (4.7, 6.7)	<0.001	4.93 (4.1, 6.0)	<0.001
<b>Gender</b>				
Male	1		1	
Female	1.12 (1.0,1.2)	0.003	1.04 (0.9, 1.1)	0.334
<b>Education</b>				
No formal education	2.02 (1.6,2.4)	<0.001	1.83 (1.5, 2.3)	<0.001
Primary	1.85 (1.49, 2.3)	<0.001	1.39 (1.1 , 1.8)	0.006
Secondary	1.89 (1.47,2.4)	<0.001	1.57 (1.2 , 2.0)	0.001
Graduation	1		1	
<b>Area</b>				
Urban	1		1	
Rural	1.26 (1.16, 1.34)	<0.001	1.08 (0.9, 1.2)	0.084
<b>Family History of diabetes</b>				
Negative	1		1	
Positive	3.98 (3.6,4.3)	<0.001	3.94 (3.6, 4.3)	<0.001
<b>Smoking</b>				
Never	1		1	
Ex- Smoker	1.39 (1.1, 1.8)	0.006	1.13 (0.9 , 1.5)	0.323
Current Smoker	1.13 (0.9,1.3)	0.14	1.06(0.9, 1.3)	0.571
<b>Systolic BP</b>	1.02 (1.021, 1.026)	<0.001	1.01 (1.01, 1.02)	<0.001
<b>Diastolic BP</b>	1.01 (1.01, 1.02)	<0.001	0.99 (0.9 , 1.0)	0.310
<b>BMI</b>				
Underweight (<18.5)	0.64 (0.4, 0.9)	0.001	0.71 (0.5, 1.0)	0.077
Normal (18.5-<25)	1		1	
Overweight (25-<30)	1.08 (0.9,1.2)	0.06	1.06 (0.9, 1.1)	0.182
Obese1 (30-<35)	1.57 (1.4,1.7)	<0.001	1.54 (1.3, 1.7)	<0.001
Obese 2 (35-<40)	2.22 (1.8,2.6)	<0.001	2.13 (1.7, 2.6)	<0.001
Obese 3 ( $\geq$ 40)	3.07 (2.2,4.2)	<0.001	2.44 (1.7, 3.5)	<0.001
<b>Waist circumference *</b>				
Normal Weight	1		1	
Over weight	1.18 (1.04, 1.34)	0.01	0.98 (0.8, 1.1)	0.774
Obese	2.46 (2.19, 2.77)	<0.001	1.86 (1.6, 2.2)	<0.001
<b>Waist to Hip Ratio *</b>				
Normal Weight	1		1	

1  
2  
3  
4  
5  
6

Over weight	1.02 (0.92, 1.13)	0.40	0.8 (0.7, 0.9)	<0.001
Obese	1.27 (1.07, 1.51)	0.005	1.13 (0.9, 1.4)	0.205

---

7 \* n for WC & WHR is 12865.  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Table 3: Summary statistics for diabetes diagnosed by HbA1c compared to diabetes diagnosed by 2hrs OGTT (n=1,027)

		[95% Confidence Interval]		
Prevalence	Pr (A)	40.6%	37.6%	43.7%
Sensitivity	Pr (+ A)	84.7%	80.8%	88.0%
Specificity	Pr (- N)	87.2%	84.3%	89.8%
ROC area	(Sens. + Spec.)/2	0.86	0.84	0.88
Likelihood ratio (+)	Pr (+ A)/Pr (+ N)	6.62	5.36	8.18
Likelihood ratio (-)	Pr (- A)/Pr (- N)	0.18	0.14	0.22
Odds ratio	LR (+)/LR (-)	37.62	26.34	53.73
Positive predictive value	Pr (A +)	81.9%	77.9%	85.4%
Negative predictive value	Pr (N -)	89.3%	86.5%	91.6%

ew only

1  
2  
3 Figure 1: Prevalence of diabetes (diagnosed by HbA1C  $\geq$ 6.5 % DCCT aligned /48 mmol/mol  
4 IFCC units) by regions of Pakistan, age, gender, education, family history of diabetes,  
5 hypertension, waist circumference, waist to hip ratio and body mass index (n=18,856).  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1: Prevalence of type 2 diabetes (diagnosed by HbA1C ≥6.5 % DCCT aligned /48 mmol/mol IFFC units) by regions of Pakistan, age, gender, education, family history, hypertension, WC, WHR and BMI (n=18,856)

304x221mm (72 x 72 DPI)

# Reporting checklist for cross sectional study.

Based on the STROBE cross sectional guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the STROBE cross sectional reporting guidelines, and cite them as:

von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

		Reporting Item	Page Number
Title	#1a	Indicate the study's design with a commonly used term in the title or the abstract	1
Abstract	#1b	Provide in the abstract an informative and balanced summary of what was done and what was found	3
Background / rationale	#2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	#3	State specific objectives, including any prespecified hypotheses	5
Study design	#4	Present key elements of study design early in the paper	6
Setting	#5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6
Eligibility criteria	#6a	Give the eligibility criteria, and the sources and methods of selection of participants.	6-7



1		#7	Clearly define all outcomes, exposures, predictors, potential	7
2			confounders, and effect modifiers. Give diagnostic criteria, if	
3			applicable	
4				
5				
6	Data sources /	#8	For each variable of interest give sources of data and details of	7-8
7	measurement		methods of assessment (measurement). Describe	
8			comparability of assessment methods if there is more than one	
9			group. Give information separately for for exposed and	
10			unexposed groups if applicable.	
11				
12				
13				
14	Bias	#9	Describe any efforts to address potential sources of bias	8
15				
16				
17	Study size	#10	Explain how the study size was arrived at	6
18				
19	Quantitative	#11	Explain how quantitative variables were handled in the	7
20	variables		analyses. If applicable, describe which groupings were chosen,	
21			and why	
22				
23				
24	Statistical	#12a	Describe all statistical methods, including those used to control	8
25	methods		for confounding	
26				
27				
28		#12b	Describe any methods used to examine subgroups and	8
29			interactions	
30				
31				
32		#12c	Explain how missing data were addressed	8
33				
34				
35		#12d	If applicable, describe analytical methods taking account of	8
36			sampling strategy	
37				
38				
39		#12e	Describe any sensitivity analyses	8
40				
41	Participants	#13a	Report numbers of individuals at each stage of study—eg	8-9
42			numbers potentially eligible, examined for eligibility, confirmed	
43			eligible, included in the study, completing follow-up, and	
44			analysed. Give information separately for for exposed and	
45			unexposed groups if applicable.	
46				
47				
48				
49		#13b	Give reasons for non-participation at each stage	8
50				
51				
52		#13c	Consider use of a flow diagram	6
53				
54	Descriptive data	#14a	Give characteristics of study participants (eg demographic,	8-9
55			clinical, social) and information on exposures and potential	
56			confounders. Give information separately for exposed and	
57			unexposed groups if applicable.	
58				
59				
60				

1		#14b	Indicate number of participants with missing data for each	8-9
2			variable of interest	
3				
4				
5	Outcome data	#15	Report numbers of outcome events or summary measures.	9
6			Give information separately for exposed and unexposed	
7			groups if applicable.	
8				
9				
10	Main results	#16a	Give unadjusted estimates and, if applicable, confounder-	9
11			adjusted estimates and their precision (eg, 95% confidence	
12			interval). Make clear which confounders were adjusted for and	
13			why they were included	
14				
15				
16				
17		#16b	Report category boundaries when continuous variables were	9
18			categorized	
19				
20				
21		#16c	If relevant, consider translating estimates of relative risk into	9
22			absolute risk for a meaningful time period	
23				
24	Other analyses	#17	Report other analyses done—e.g., analyses of subgroups and	9
25			interactions, and sensitivity analyses	
26				
27				
28	Key results	#18	Summarise key results with reference to study objectives	9
29				
30				
31	Limitations	#19	Discuss limitations of the study, taking into account sources of	11
32			potential bias or imprecision. Discuss both direction and	
33			magnitude of any potential bias.	
34				
35				
36	Interpretation	#20	Give a cautious overall interpretation considering objectives,	11
37			limitations, multiplicity of analyses, results from similar studies,	
38			and other relevant evidence.	
39				
40				
41	Generalisability	#21	Discuss the generalisability (external validity) of the study	11
42			results	
43				
44				
45	Funding	#22	Give the source of funding and the role of the funders for the	12
46			present study and, if applicable, for the original study on which	
47			the present article is based	
48				
49				

The STROBE checklist is distributed under the terms of the Creative Commons Attribution License CC-BY. This checklist was completed on 04. July 2018 using <http://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)

# BMJ Open

## DIABETES PREVALENCE SURVEY OF PAKISTAN (DPS- PAK): Prevalence of type 2 Diabetes Mellitus and pre-diabetes using HbA1c: A population-based survey from Pakistan

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-025300.R1
Article Type:	Research
Date Submitted by the Author:	21-Nov-2018
Complete List of Authors:	Aamir, Azizul Hasan; Hayatabad Medical Complex, Diabetes & Endocrinology & metabolic diseases Ul-Haq, Zia; Khyber Medical University, Institute of Public Health & Social Sciences; University of Glasgow Institute of Health and Wellbeing, Public Health Mahar, Saeed ; National Institute of Cardiovascular Diseases, Endocrinology Qureshi, Faisal; Al-Khaliq Hospital, Multan, Endocrinology Ahmad, Ibrar; Lady Reading Hospital, Endocrinology ward Jawa, Ali; Pakistan Institute of Medical Sciences, Endocrinology Sheikh, Aisha ; Aga Khan University, Endocrinology Raza, Abbas; Shaukat Khanum Memorial Cancer Hospital and Research Centre, Endocrinology Fazid, Sheraz; Khyber Medical University, Institute of Public Health & Social Sciences Jadoon, Zahid; Hayatabad Medical Complex Department of Ophthalmology, Epidemiology Ishtiaq, Osama; Shifa College of Medicine, Endocrinology Safdar, Nauman; Social and health inequalities Network, Social work Afridi, Hussain; Hayatabad Medical Complex, Department of Diabetes, Endocrinology and Metabolic Diseases Heald, Adrian; Leighton Hospital, Medicine
<b>Primary Subject Heading</b>:	Diabetes and endocrinology
Secondary Subject Heading:	Epidemiology
Keywords:	Type 2 Diabetes Mellitus, diabetes, HbA1c, Pakistan, pre-diabetes, Prevalence

SCHOLARONE™  
Manuscripts

**Title Page:****DIABETES PREVALENCE SURVEY OF PAKISTAN (DPS- PAK):  
Prevalence of type 2 Diabetes Mellitus and pre-diabetes using HbA1c: A  
population-based survey from Pakistan**

Azizul Hasan Aamir<sup>1</sup>, Zia Ul-Haq<sup>2,3</sup>, Saeed A. Mahar<sup>4</sup>, Faisal Masood Qureshi<sup>5</sup>, Ibrar Ahmad<sup>6</sup>, Ali Jawa<sup>7</sup>, Aisha Sheikh<sup>8</sup>, Abbas Raza<sup>9</sup>, Sheraz Fazid<sup>2</sup>, Zahid Jadoon<sup>10</sup>, Osama Ishtiaq<sup>11</sup>, Nauman Safdar<sup>12</sup>, Hussain Afridi<sup>1</sup>, Adrian H. Heald<sup>13</sup>

<sup>1</sup> Department of Diabetes, Endocrinology and Metabolic Diseases, Hayatabad Medical Complex, Peshawar, Khyber Pakhtunkhwa, Pakistan

<sup>2</sup> Institute of Public Health & Social Sciences, Khyber Medical University, Peshawar, KP, Pakistan

<sup>3</sup> Institute of Health and Wellbeing, University of Glasgow, Glasgow G12 8RZ, UK

<sup>4</sup> National Institute of cardiovascular diseases, Karachi

<sup>5</sup> Al-Khaliq Hospital, Multan.

<sup>6</sup> Lady Reading hospital, Peshawar.

<sup>7</sup> Pakistan Institute of medical sciences, Islamabad.

<sup>8</sup> Aga Khan University Hospital, Karachi.

<sup>9</sup> Shaukat Khanum Hospital, Lahore.

<sup>10</sup> Hayatabad Medical Complex, Peshawar.

<sup>11</sup> Shifa International Hospital, Islamabad.

<sup>12</sup> Social and Health Inequalities Network, Islamabad.

<sup>13</sup> The school of medicine and Manchester academic sciences centre, University of Manchester, Manchester, United Kingdom.

1. Azizul Hasan Aamir: [drahaamir@gmail.com](mailto:drahaamir@gmail.com), MBBS, MRCP, FRCP, FACE
2. Zia Ul-Haq: [drzia@kmu.edu.pk](mailto:drzia@kmu.edu.pk), MBBS, MPH, PhD
3. Saeed A. Mahar: [saeedamahar@yahoo.com](mailto:saeedamahar@yahoo.com). FRCP
4. Faisal Qureshi: [f-qureshi@hotmail.com](mailto:f-qureshi@hotmail.com). FACE
5. Ibrar Ahmed: [ibrar2127@hotmail.com](mailto:ibrar2127@hotmail.com). FCPS
6. Ali Jawa: [alijawa@gmail.com](mailto:alijawa@gmail.com). FACE
7. Aisha Shiekh: [aisha.sheikh@aku.edu](mailto:aisha.sheikh@aku.edu). FCPS
8. Abbas Raza: [sabbasraza@hotmail.com](mailto:sabbasraza@hotmail.com). FACE
9. Osama Ishtiaq: [docosama@gmail.com](mailto:docosama@gmail.com). FCPS
10. Sheraz Fazid: [sherazvs@gmail.com](mailto:sherazvs@gmail.com) PhD Scholar, MPH
11. Zahid Jadoon: [zahid@pico.org.pk](mailto:zahid@pico.org.pk). MSc
12. Nauman Safdar: [safdar.nauman@gmail.com](mailto:safdar.nauman@gmail.com). PhD
13. Hussain Afridi: [mhussainfr@gmail.com](mailto:mhussainfr@gmail.com). FCPS
14. Adrian H. Heald: [adrian.heald@manchester.ac.uk](mailto:adrian.heald@manchester.ac.uk). FRCP

1  
2  
3 Correspondence to:  
4

5 Prof. Azizul Hasan Aamir

6 Head of the Department of Diabetes, Endocrinology and Metabolic Diseases

7 Hayatabad Medical Complex

8 Phase 5, Hayatabad, Peshawar, Pakistan

9 e-mail:drahaamir@gmail.com

10 Tel: +92 -91- 921-7794  
11  
12  
13  
14  
15

16 Word count (main text) 3483

17 Figures 01

18 Tables 03  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

### Objectives

We conducted a Pakistan-wide community-based survey on the prevalence of type-2 diabetes using HbA1c as the screening test. The aim was to cover all regions of Pakistan and the full spectrum of demographic situations.

### Design, settings and participants

Multi-staged stratified cluster sampling was used for the representative selection of people aged  $\geq 20$  years, residing in 378 sampled clusters of 16 randomly selected districts. Eligible participants were called to the nearby field clinic for HbA1c analyses. OGTT was conducted on a subsample of the participants. Overall and stratified prevalence of type-2 diabetes and its association with risk factors were estimated using logistic regression models through STATA-14.

### Main outcome measures

Prevalence of pre-diabetes and type 2 diabetes

### Results

Of 18,856 eligible participants the prevalence of pre-diabetes was 10.91% (95% CI 10.46, 11.36,  $n=2,057$ ) and type-2 diabetes was 16.98% (95%CI 16.44, 17.51,  $n=3,201$ ). Overall, the mean HbA1c level was 5.62% (SD 1.96), and among newly diagnosed was 8.56% (SD 2.08). The prevalence was highest in age 51-60 years (26.03%,  $p<0.001$ ), no formal education (17.66%,  $p<0.001$ ), class-3 obese (35.09%,  $p<0.001$ ), family history (31.29%,  $p<0.001$ ) and female (17.80%,  $p=0.009$ ). On multivariate analysis, there was a significant dose-response relation of type-2 diabetes with age, BMI, central obesity, family history, and hypertension and an inverse relation with education. On a subsample ( $n=1,027$ ), summary statistics for diagnosis of diabetes on HbA1c showed a sensitivity of 84.7%, specificity of 87.2%, and ROC area 0.86, compared to OGTT.

### Conclusions

The prevalence of type-2 diabetes and pre-diabetes is much higher than previously thought in Pakistan. Comprehensive strategies need to be developed to incorporate screening, prevention and treatment of type 2 diabetes at a community level.

### Key words (mesh terms):

Type 2 Diabetes Mellitus, diabetes, Prevalence, HbA1c, OGTT, obesity, pre-diabetes, Pakistan

### Strength and limitations of this study

#### **Strengths:**

Our study has the strength that we carried out HbA1c on all participants and OGTT on a subsample.

Furthermore this is the largest ever national prevalence study of type-2 diabetes mellitus from Pakistan and the first community based national study to use HbA1c as the diagnostic tool.

#### **Limitations:**

The relatively low number (n=1,027) of 75g OGTT. Nevertheless the specificity and sensitivity of HbA1c versus OGTT was good.

We had to exclude 16% of recruited participants recruited because of anaemia.

## Background

Type 2 Diabetes Mellitus is one of the most common public health issues worldwide and its incidence is on the rise particularly in middle and low-income countries[1]. When associated with complications, type-2 diabetes can have a profound impact on the person with consequences also for the society as a whole. It was previously thought to be a disease of the affluent and mostly prevalent in urban areas but due to urbanization and a more sedentary lifestyle for many people, it has affected developing nations, including Pakistan[2].

Pakistan is a South Asian country with an area of 796,095 km<sup>2</sup> and a population of 207.7 million people[3]. In terms of population, Pakistan is the 6<sup>th</sup> most populous country and is the 36<sup>th</sup> largest country by geographical area in the world. Before 2018, the only previous national diabetes survey in Pakistan in 1999 (published in 2007), reported the prevalence of type-2 diabetes as 11% using the Oral Glucose Tolerance Test (OGTT)[4 5]. Part of the same survey separately reported the prevalence of type-2 diabetes in different provinces of Pakistan [4 6-8]. The International Diabetes Federation (IDF) reported in its Atlas 20 the prevalence for Pakistan to be 6.8%, aged 20-79[9], but health care professionals with local insight always believed this to be an underestimate. Subsequently there were conflicting findings with prevalence ranges from 7.2%-19.21% in different regions of the country[5].

The American Diabetes Association (ADA) criteria for the diagnosis of diabetes require either fasting plasma glucose (FPG) or 75gm OGTT which is time-consuming, requires fasting and may not always be reproducible[10 11]. In 2009, the International Expert committee on diabetes proposed new diagnostic criteria based on Glycated Haemoglobin (HbA1c), which captures chronic glucose exposure[12]. The proposed diagnostic threshold of 6.5% (48mmol/mol) was based on retinopathy risk at different levels of HbA1c as was the case with FPG and OGTT. This report was followed by a recommendation from the ADA. An HbA1c level of 6.5% (48mmol/mol) was agreed to be a diagnostic cut-off for the diagnoses of diabetes[13].

A previous national level type-2 diabetes survey was conducted in 1999 with a sample size of 5433 using OGTT. In the study described in this paper, we investigated the prevalence of type-2 diabetes (using the HbA1c test) and its distribution across gender, age, rural and urban, education, Body Mass Index (BMI) WHO and Asian cut-offs, family history, smoking, and blood pressure among a large sample across Pakistan, aged 20 years and above. A sub subsample was tested to explore the diagnostic summary statistics for diagnosis of type-2 diabetes on HbA1c, compared to 2 hours OGTT.



## Methods

The Department of Diabetes, Endocrine and Metabolic Diseases, Hayatabad and Department of Health, Government of Khyber Pakhtunkhwa, Pakistan with technical support from Institute of Public Health, Khyber Medical University Peshawar Pakistan, University of Manchester UK and Pakistan Endocrine Society conducted a nationwide cross-sectional study for the prevalence of type-2 diabetes starting in April 2017 and completed in November 2017. Three teams under the supervision of epidemiologists were created and the field workers trained to take basic demographic data on the sample to be screened. These national samples were selected based on a stratified two-stage cluster design, including all metropolitan cities of Pakistan and randomly selected districts (both rural and urban settings) within each province. The sample included districts from central and south of Punjab province (Lahore, Multan, Bahawalpur, Rahim Yar Khan), interior Sindh (Larkana, Dadoo, Sukkur), central Sindh (Karachi), northern Khyber Pakhtunkhwa (KP) (Haripur), central (Peshawar) and southern KP province (Karak), Baluchistan province (Quetta), capital territory (Rawalpindi-Islamabad), Azad Jammu Kashmir (Muzaffarabad), Frontier Region Peshawar and the Khyber Agency in Federal Administered Tribal Area (FATA).

### Sample size and sampling methodology:

The sample size was estimated for the provinces of the country based on recent census results. The sample size was estimated based on an expected prevalence of 12% with 20% relative precision and a design effect of 2[6]. For a 95% confidence interval and an additional adjustment of 32% for non-responders, keeping in view an exclusion rate due to an expected high prevalence of anaemia, the sample size was 4407 approximated to 4500 in order to have 50 subjects from each cluster. All provinces were included as was the Federal territory. AJK and FATA were considered as one province for the survey purpose because of their small size of the population. The number of eligible subjects was  $4500 \times 5 = 22500$ .

Three districts were randomly selected from each province and the sample size was equally divided on these districts. Fifteen hundred subjects (30 clusters, 50 subjects per cluster) were examined in each district. The sample was proportionately divided amongst urban and rural areas. Probability proportionate to size (PPS) method was used to select clusters from villages in the rural settings of the district. In urban settings, clusters were selected from charges and circles (defined in the national census) using the PPS method.

Maps were obtained from the census office of selected villages/charges/circles (V/C/C). Maps of each V/C/C was divided into equal segments such that each segment had approximately 50 persons 20 years and above. One segment was randomly selected and every house within the segment was included. All persons 20 and above living in that house were examined until the 50 number was reached. Any person who was absent on the day of survey until evening, was terminally ill, who fitted into exclusion criteria or who refused were marked as non-responders.

Ethical approval was granted from Khyber Medical University ethical board (DIR/KMU-EB/SP/000395). Conditions that may affect HbA1c including anaemic subjects with haemoglobin less than 12gm/dl in women and less than 14 gm/dl in men, self-reported renal and hepatic dysfunction, recent blood transfusion, and use of erythropoietin, age below 20 years or refusal to participate resulted in exclusion. Face to face interview was conducted at the participant's home to collect information on demographics (including age, gender, residential area, formal education, family history of diabetes, and smoking status) using a paper questionnaire in local languages. Eligible participants were called to a central point established in the hujra (local public gathering place) where their haemoglobin was tested using the Mission Plus Haemoglobin Meter (reflectance photometer technique) Acon Laboratories, Inc., San Diego (coefficient of variance CV: 3%). Blood pressure was measured using an automated digital blood pressure monitor Konfort Model AS-351 in the lying position with the average of three readings was recorded. Weight in kilograms and height in meters was recorded and used to calculate Body Mass Index.

Diabetes status was assessed for HbA1c on blood samples using the National Glycohemoglobin Standardization Program (NGSP) certified FIA 8000 immunoassay analyser (lateral flow chromatography colloidal gold) traceable to diabetes control and complication trial (DCCT) reference method (CV: 3-5%). To compare the results from HbA1c, 2 hours OGTT was conducted on a random sample of participants from all clusters (n=1,027) in the specified standard laboratory using Cobas C311 Roche Diagnostics, Mannheim, Germany. Participants were given vouchers for free OGTT test within 7 days in a nearby laboratory using Cobas C311 Roche Diagnostics.

### Definitions

Age was categorised into six groups: 20-30, 31-40, 41-50, 51-60 and 61 and above years. The residential area was classified as urban and rural based on local government criteria. Formal education status was self-reported was categorized as no formal education, primary, secondary and graduation/post graduation. BMI was categorised on WHO criteria into underweight (<18.5 kg/m<sup>2</sup>), normal weight (18.5-24.9 kg/m<sup>2</sup>), overweight (25-29.9 kg/m<sup>2</sup>), class I obese (30-34.9 kg/m<sup>2</sup>), class II obese (35-39.9 kg/m<sup>2</sup>), and class III obese (>40 kg/m<sup>2</sup>) (World Health Organization., 1995). Waist Circumference (WC) was categorized into normal-weight (0-93.99), overweight (94-102) and obese (102 & above). Waist to hip ratio (WHR) was categorized into normal-weight (0-0.89), overweight (0.90-0.99) and obese (1 & above) [14]. The family history of diabetes was categorised to negative or positive on the basis of the participant's self-reporting, based on physician's diagnoses. Smoking status was categorized as never, ex or current smoker. Systolic and diastolic blood pressure was measured using a standard procedure and was Hypertension was defined on a blood pressure measurement of  $\geq 140/90$  mmHg or anti-hypertensive medication. Patients were considered as known type-2 diabetes on the basis of self-reporting and or being on dietary or exercise advice, oral anti-diabetes medications or insulin.

This self-reported group of patients could either be on single medications or on different drug combinations or diet and exercise therapy.

Type 2 diabetes was diagnosed based on HbA1c results keeping the WHO levels of non diabetes (<5.69 % DCCT aligned/38 mmol/mol IFFC units), pre-diabetes (5.7-6.49% DCCT aligned/ 39-47mmol/mol IFFC units), diabetes ( $\geq 6.5$  % DCCT aligned /48 mmol/mol IFFC units). For univariate and multivariate logistic regression models, diabetes was dichotomized to No (0; HbA1c level <6.5) and Yes (1; HbA1c level  $\geq 6.5$ ).

### Statistical Analyses

Differences in the characteristics of participants by diabetes category were analysed using the  $\chi^2$  test for categorical data and ANOVA for continuous data. We examined the association between diabetes and risk factors i.e., age, gender, residence area, education, BMI, family history of diabetes, smoking, systolic and diastolic blood pressure, using univariate and multivariate logistic regression models. Multivariate regression analysis included all these variables.

Taking OGTT as the standard on a sub subsample, the diagnostic summary statistics (sensitivity, specificity, ROC area, positive and negative predictive value) for the diagnosis of diabetes using HbA1c were determined. All statistical analyses were performed using Stata version 14 (Stata Corp, College Station, Texas). Statistical significance was defined as  $p < 0.05$  and analysis were adjusted for the cluster design.

### **Patient and Public Involvement statement:**

Patients were not involved in the study conception or design. There was consultation with interested representative public bodies but not with individual members of the public.

### **Results**

Of the 22,500 participants, 3,644 (16%) were anaemic and therefore excluded from the study. Out of the remaining, 18,856 participants aged 20 and above, were actually examined from 378 clusters of which 216 were rural generating a response rate of 84%. The mean age was 45.23 years (standard deviation [SD] 13.97 years). 10,116 (53.55%) were men, 4,148 (21.96%) were hypertensive and those with higher blood pressure were advised to check their blood pressure by visiting their doctors. 13,834 (73.24%) had no formal education, and 1,209 (6.40%) had graduated. 6,010 (31.81%) had a family history of type-2 diabetes. Overall on WHO cut-off 345 (1.83%) were underweight, 6,839 (36.20%) normal-weight, 8,038 (42.55%) overweight, 2,864 (15.16%) class I obese, 633 (3.35%) class II obese, and 172 (0.91%) class III obese. On waist circumference (WC) cut-off (n=12865) 8,574 (66.64%) were normal-weight, 2,318 (18.02%) were overweight and 1,974 (15.34%) were obese. On central obesity cut-off (WHR, n=12865) 4,271 (33.20%) were normal weight, 7,467 (58.04%) were overweight and 1,127 (8.76%) were

1  
2  
3 obese. Mean systolic blood pressure was 126.30mmHg (SD 14.2) and diastolic blood pressure  
4 was 83.24mmHg (SD 10.2).  
5  
6  
7

8 Overall, 3,201 subjects (16.98%, 95%CI 16.44, 17.51) had type-2 diabetes based on HbA1c  
9 screening. Pre-diabetes was present in 2,057 subjects 10.91% (95% CI 10.46, 11.36). The mean  
10 HbA1c level of the entire cohort (n=18856) was 5.62% (SD 1.96), among known type-2 diabetes  
11 (n=2179) had 8.68% (SD 2.70) and newly diagnosed type-2 diabetes (n=1577) had 8.56%  
12 (SD2.08). The prevalence of diabetes differed significantly by age, education, BMI, WC, WHR,  
13 family history, and blood pressure (Table 1) (Figure 1). The prevalence of diabetes was highest  
14 in age 51-60 years (26.03%, p<0.001), no formal education (17.73%, p<0.001), class 3 obese  
15 (32.19%, p<0.001), and with a positive family history of diabetes (31.34%, p<0.001) (Figure 1).  
16 There were also statistically significant differences in diabetes prevalence by gender (female  
17 17.85%, p=0.01), rural/urban (rural 19.09%, p<0.001) and thatsmoking status (p=0.008).  
18  
19  
20  
21

22 On univariate logistic regression analysis, there was a significant association between age,  
23 gender, education, BMI category, family history, blood pressure and type 2 diabetes (p<0.005)  
24 (Table 2).  
25  
26  
27

28 On multivariate logistic regression, there was significantly higher risk of diabetes with age  
29 (adjusted Odds Ratio [OR] 2.03, 3.39, 4.87 and 4.93, p< 0.001, aged 31-40 years, 41-50 years,  
30 51-60 years and 61 years and above respectively, compared to age 20-30 years), BMI (adjusted  
31 OR 1.54, 2.13, 2.44,p-value <0.001 for class 1, class II and class III obese respectively,  
32 compared to normal weight) with evidence of a dose-response relationship. Similarly, there was  
33 a significantly higher risk of diabetes with lower educational attainment (adjusted OR 1.83, 1.39,  
34 1.57, no formal education, primary and secondary education respectively, compared to  
35 graduates). There was a significantly higher risk of diabetes in people with a positive family  
36 history (adjusted OR 3.94, 95% CI 3.6, 4.3 p<0.001), than with no family history of diabetes.  
37 There was no significant association with smoking and rural/urban area.  
38  
39  
40  
41

42 Among 1,029 participants who were tested for 2hrs OGTT, in addition to HbA1c, the mean 2  
43 hours OGTT was 200.26 (SD 91.7), and the median was 178 (inter-quartile range 100). Taking  
44 the OGTT as the gold standard, HbA1c recommended cut-off for diabetes showed a sensitivity  
45 of 84.7% (95% CI 80.8, 88) and Specificity of 87.2% (95% CI 84.3, 89.8%), ROC area 0.86  
46 (95% CI 0.84, 0.88), positive predictive value 81.9% (95% CI 77.9, 85.4), and negative  
47 predictive value 89.3 (86.5, 91.6) (Table 3).  
48  
49  
50  
51

## 52 Discussion:

53 This is the first community based national study done in the region based on HbA1c and with the  
54 eligible 18,856 subjects from Pakistan this is the largest study to date from that country. The  
55 prevalence of type-2 diabetes all across Pakistan was 16.98% (95%CI 16.44, 17.51) and pre-  
56  
57  
58  
59  
60

1  
2  
3 diabetes was 10.91% (95% CI 10.46, 11.36). This is higher than found in the only previous  
4 national survey conducted in 1999 (n=5433) using OGTT. There was a significantly higher risk  
5 of type-2 diabetes with increasing systolic blood pressure, age, BMI, WC, WHR with evidence  
6 of a dose-response relationship. Similarly, there was a significant inverse relationship of type-2  
7 diabetes with the level of formal education. The risk of diabetes increased 2.68 times with a prior  
8 family history. The HbA1c level had good sensitivity and specificity level for the diagnoses of  
9 type-2 diabetes compared to a 2-hour OGTT level and is therefore valid in community settings  
10 for screening purposes.  
11  
12  
13  
14

15 We have noted the findings of Basit et al [15]. The methodology for that study was based on 75g  
16 Oral Glucose Tolerance diagnostic test for glucose handling as opposed to HbA1c used in our  
17 study. While the prevalence of diabetes + pre-diabetes is different in the two studies, the point  
18 that both studies make is that both diabetes and pre-diabetes are much more prevalent than  
19 previously thought.  
20  
21  
22

23 The previous national prevalence study conducted in 1999 used OGTT where almost 80% of the  
24 subjects were women as the test was conducted in the morning time [4]. In contrast, our study  
25 screening was done all through the day so that working men had an equal opportunity to be part  
26 of the study. They constituted 50% of the study population. OGTT is the gold standard for the  
27 type 2 diabetes screening but because of the length of time which is required for the test and the  
28 fact that person has to be fasting, it is very difficult to perform in many community settings in  
29 Pakistan. Also, the high temperatures in South Asia make it difficult to keep the sample stable  
30 for transportation to the laboratory. To minimize the effect of temperature and transportation  
31 errors on HbA1c, all tests were conducted in the field.  
32  
33  
34

35 Recently a study carried out in 15 states of India showed that the prevalence of type-2 diabetes  
36 ranged between 4%-13.6% and showed variation due to age, male sex, obesity and family history  
37 using capillary FBG for diagnosis [16]. A capillary blood sample for epidemiological studies is  
38 not an ideal test but the authors acknowledged the logistic hindrance in carrying out venous  
39 sample test in the field. A high prevalence in another Indian study was reported ranging from  
40 12.1-14% for diabetes using OGTT on a sample size of 11,216 subjects [17].  
41  
42  
43

44 A study conducted in Bangladesh was based on capillary fasting level found a prevalence of  
45 type-2 diabetes of 4.3% in a rural setting [18]. Risk factors were positive family history for  
46 diabetes, age, high BMI and low socio-economic status, similar to our study. Although these are  
47 geographically distant areas, the risk factors showed commonality in both studies, which  
48 suggests these risk factors as an important tool for mass screening [19].  
49  
50  
51

52 The age sex-standardized prevalence of type-2 diabetes for Sri Lankans was 10.3% based on  
53 OGTT [20]. The risk factors were almost the same as seen in our study. The investigators found  
54 dysglycaemia in almost 21.8% participants and predicted that this would lead to a higher  
55  
56  
57

1  
2  
3 prevalence of T2DM in the years to come. Another study from Sri Lanka indicated a prevalence  
4 of 14.2% basis of FBG[21]. FBG as well as, OGTT blood glucose levels, may not be  
5 reproducible in an epidemiological survey if the individual are changing lifestyle in terms of diet  
6 and exercise. The use of HbA1c in our study makes our study more scientific, addressing issues  
7 pertaining to sampling errors in the local environment.  
8  
9

10  
11 The Asian population is known to have a significantly higher risk of developing diabetes and its  
12 related complications as predicted by IDF projections[1]. It makes it very important from a  
13 public health point of view to identify high-risk individuals at an early stage. The HbA1c test has  
14 been used successfully in community settings[22]. A national health survey New Zealand in  
15 2008-9 used HbA1c to identify high-risk individuals with diabetes and pre-diabetes[23]. A study  
16 in Japan revealed that a combination of tests including FBG and HbA1c yields more diabetes  
17 cases compared to any of these tests alone[24].  
18  
19

20  
21 WHO experts have accepted HbA1c as a diagnostic tool provided quality assurance tests are in  
22 place and there are no conditions present, which preclude its accurate measurement. The New  
23 Zealand Society for the study of Diabetes and the Australian Diabetes Society have already  
24 endorsed HbA1c as a test for the diagnosis of diabetes[25 26]. Recently a prevalence study done  
25 in Korea concluded that FBG testing results in underestimation of diabetes and pre-diabetes[27].  
26 This study suggested the use of standardized HbA1c as a diagnostic tool for diagnosis of type-2  
27 diabetes.  
28  
29  
30

31  
32  
33 We found that HbA1c level had a good sensitivity and specificity level for diagnoses of diabetes  
34 compared to 2-hrs OGTT level. HbA1c has the advantage of being a simple test and less time  
35 consuming, making it an ideal test for community surveys in our populations. In Pakistan, as  
36 there is no effective primary care (general/ family practice) structure most of the population does  
37 not undergo primary screening for diabetes. Sometimes as the diagnosis is not made, people  
38 may present to tertiary care with florid complications.  
39  
40  
41

42 Thus there is a strong case for applying HbA1c for screening purposes in the community setting.  
43 There will always be an argument about the cost of the test and whether this to be used for  
44 screening purposes. However particularly those at social disadvantage need to be undergo  
45 screening to improve the diagnosis timely treatment of diabetes[28]. Needless to say, early  
46 diagnosis will also reduce diabetes-related complications.  
47  
48  
49

#### 50 Strengths and limitations

51 Our study has the strength that we carried out HbA1c on all participants and OGTT on a  
52 subsample. Furthermore this is the largest ever national prevalence study of type-2 diabetes  
53 mellitus from Pakistan and the first community based national study to use HbA1c as the  
54 diagnostic tool.  
55  
56  
57

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Limitations are the relatively low number (n=1,027) of 75gOGTT. Nevertheless the specificity and sensitivity of HbA1c vs OGTT was good. We had to exclude 16% of recruited participants recruited because of anaemia.

The central Government of Pakistan has developed and agreed on Non- Communicable Diseases (NCD) National Action Plan including diabetes, however, it was never implemented. After the 18<sup>th</sup> Amendment in the constitution of Pakistan in 2010, provinces are responsible for making and implementing their own health policies and the role of central Government is limited to coordination among the different provinces[29]. There is a dire need that based on the agreed NCD National Action Plan each province should build their capacity for implementing it at both primary and secondary level. Pakistan is a signatory to the Sustainable Development Goals 2030document which outlines among its goals, increasing access to universal health coverage, increasing coverage of health insurance program and adopting a family medicine approach. When implemented, these will not only be major steps towards prevention and control of diabetes but all non-communicable diseases.

### **Conclusions:**

This national diabetes prevalence study is the first one in the region using HbA1c identified a huge population of type-2 diabetes and pre-diabetes group. The prevalence of type-2 diabetes and pre-diabetes is much higher than previously thought in Pakistan. Comprehensive strategies need to be developed to incorporate screening, prevention and treatment of type 2 diabetes at community level. Those who are obese, with no formal education, older, family history of diabetes and hypertensive merit close attention and timely intervention.

HbA1c is an applicable test in community settings in developing countries and it has a good correlation with 2 hours OGTT. Our findings have the potential to influence policy in developing countries and induce a shift towards the prevention and control of non-communicable diseases.

1  
2  
3 **Acknowledgements** Khyber Pakhtunkhwa Government of Pakistan and field staff for supporting  
4 survey the Pakistan Endocrine Society for technical and logistic support in this survey,  
5 The Institute of Public Health, Prof Dr Zia and his team particularly Dr Basharat Hussain Shah at  
6 Khyber Medical University for statistical support and the University of Manchester for help in  
7 data analysis and in reviewing the manuscript.  
8  
9

10 **Contributors** AHA, ZUH conceived the study. AHA, SM, FQ, AS, AJ, OI, AR, IA, HA  
11 collected the data. ZJ, NS study design and data monitoring. ZUH, AHA, SF, AH, conducted the  
12 analysis and wrote the manuscript. All authors reviewed the manuscript. AHA and ZUH  
13 contributed equally.  
14

15  
16 **Funding Statement** This research received no specific grant from any funding agency in the  
17 public, commercial or not-for-profit sectors.  
18

19 **Competing interest** All authors have no competing interest to declare.  
20

21  
22 **Patient Consent** Written informed consent granted. The data is fully anonymised and neither the  
23 patient nor anyone else could identify the patient.  
24

25  
26 **Ethical approval** The ethical approval was granted from the Khyber Medical University ethical  
27 board (DIR/KMU-EB/SP/000395).  
28

29 **Data sharing statement** No additional data are available  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**References:**

1. Cho NH, Shaw JE, Karuranga S, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. *Diabetes Res Clin Pract* 2018; 138: 271-281.
2. Roglic G, Unwin N, Faurholt-Damsgaard T, Bennett PH, Bennett Ph, Faurholt-Damsgaard T, Mathers C, et al. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. *Diabetes Care* 2015; 0149-5992.
3. Provisional summary results of 6th population and housing census-2017. Secondary Provisional summary results of 6th population and housing census-2017; <http://www.pbs.gov.pk/content/provisional-summary-results-6th-population-and-housing-census-2017-0> (accessed July 2018).
4. Shera AS, Jawad F, Faurholt-Damsgaard T, Maqsood A. Prevalence of diabetes in Pakistan. *Diabetes Res Clin Pract* 2007;76(2):219-22
5. Meo SA, Zia I, Bukhari IA, et al. Type 2 diabetes mellitus in Pakistan: Current prevalence and future forecast. *JPMA* 2016;66(12):1637-42.
6. Shera AS, Rafique G, Faurholt-Damsgaard T, Khwaja IA, Khwaja Ia, Faurholt-Damsgaard T, Baqai S, et al. Pakistan National Diabetes Survey prevalence of glucose intolerance and associated factors in North West at Frontier Province (NWFP) of Pakistan. *J Pak Med Assoc* 1999;49 (9): 206-11.
7. Shera AS, Rafique G, Faurholt-Damsgaard T, Khawaja IA, Khawaja Ia, Faurholt-Damsgaard T, Baqai S, et al. Pakistan National Diabetes Survey: prevalence of glucose intolerance and associated factors in Baluchistan province. *Diab Res Clin Pra* 1999;49-58.
8. Shera AS, Rafique G, Faurholt-Damsgaard T, Khwaja IA, Khwaja Ia, Faurholt-Damsgaard T, Ara J, et al. Pakistan national diabetes survey: prevalence of glucose intolerance and associated factors in Shikarpur, Sindh Province. *Diab Med* 1995; 12 (12): 1116-21.
9. Whiting DR, Guariguata L, Weil C, et al. IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. *Diab Res Clin Pra* 2011;94(3):311-21.
10. American Diabetes A. Diagnosis and classification of diabetes mellitus. *Diabetes Care* 2014; 37:S81-S90.
11. Klein BE. Overview of epidemiologic studies of diabetic retinopathy. *Ophth Epid* 2007; 14 (4)-179-83.
12. The International Expert C. International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes. *Diabetes Care* 2009;32(7):1327-34.
13. American Diabetes A. Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 2010;33(Suppl 1):S62-S69.

14. Ahmad N, Adam SIM, Nawi AM, et al. Abdominal Obesity Indicators: Waist Circumference or Waist-to-hip Ratio in Malaysian Adults Population. *Int J of Prev Med* 2016;7:82.
15. Basit A, Fawwad A, Qureshi H, et al. Prevalence of diabetes, pre diabetes and associated risk factors: second National Diabetes Survey of Pakistan (NDSF), 2016-2017. *BMJ Open* 2018; 5;8(8):e020961.
16. Anjana RM, Deepa M, Pradeepa R, et al. Prevalence of diabetes and prediabetes in 15 states of India: results from the ICMR-INDIAB population-based cross-sectional study. *Lanc Diab End* 2017; 5(8):585-96.
17. Ramachandran A, Snehalatha C Fau - Kapur A, Kapur A Fau - Vijay V, et al. High prevalence of diabetes and impaired glucose tolerance in India: National Urban Diabetes Survey. *Diabetologia* 2001;44(9):1094-101.
18. Sayeed MA, Mahtab H Fau - Akter Khanam P, Akter Khanam P Fau - Abdul Latif Z, et al. Diabetes and impaired fasting glycemia in a rural population of Bangladesh. *Diabetes Care*; 2003; 26(4):1034-9.
19. McKeigue PM, Marmot Mg Fau - Syndercombe Court YD, Syndercombe Court Yd Fau - Cottier DE, et al. Diabetes, hyperinsulinaemia, and coronary risk factors in Bangladeshis in east London. *Br Heart J* 1988; 60(5)390-96.
20. Katulanda P, Constantine Gr Fau - Mahesh JG, Mahesh Jg Fau - Sheriff R, et al. Prevalence and projections of diabetes and pre-diabetes in adults in Sri Lanka--Sri Lanka Diabetes, Cardiovascular Study (SLDCS). *Diabet Med* 2008; 25(9) 1062-9.
21. Wijewardene K, Mohideen Mr Fau - Mendis S, Mendis S Fau - Fernando DS, et al. Prevalence of hypertension, diabetes and obesity: baseline findings of a population based survey in four provinces in Sri Lanka. *Ceylon Med J* 2005; 50(2) 62-70.
22. Grant T, Soriano Y Fau - Marantz PR, Marantz Pr Fau - Nelson I, et al. Community-based screening for cardiovascular disease and diabetes using HbA1c. *Am J Prev Med* 2004; 26(4) 271-5.
23. Coppell KJ, Mann Ji Fau - Williams SM, Williams Sm Fau - Jo E, et al. Prevalence of diagnosed and undiagnosed diabetes and prediabetes in New Zealand: findings from the 2008/09 Adult Nutrition Survey. *N Z Med J* 2013; 126(1370):23-42.
24. Takahashi Y, Noda M Fau - Tsugane S, Tsugane S Fau - Kuzuya T, et al. Prevalence of diabetes estimated by plasma glucose criteria combined with standardized measurement of HbA1c among health checkup participants on Miyako Island, Japan. *Diabetes Care* 2000; 23(8): 1092-6.
25. d'Emden MC, Shaw Je Fau - Colman PG, Colman Pg Fau - Colagiuri S, et al. The role of HbA1c in the diagnosis of diabetes mellitus in Australia. *Med J Aust* 2012; 197(4):220-1.
26. Braatvedt GD, Cundy T Fau - Crooke M, Crooke M Fau - Florkowski C, et al. Understanding the new HbA1c units for the diagnosis of Type 2 diabetes. *N Z Med J* 2012; 125 (1362) 70-80.

1  
2  
3 27. Jeon JY, Ko S-H, Kwon H-S, et al. Prevalence of Diabetes and Prediabetes according to  
4 Fasting Plasma Glucose and HbA1c. *Diabetes Metabol J* 2013;37(5):349-57.  
5

6 28. Degeling C, Rock M Fau - Rogers WA, Rogers WA. Testing relationships: ethical arguments  
7 for screening for type 2 diabetes mellitus with HbA1c. *J Med Ethics* 2012; 38(3): 180-3.  
8

9 29. Nishtar S, Boerma T Fau - Amjad S, Amjad S Fau - Alam AY, et al. Pakistan's health  
10 system: performance and prospects after the 18th Constitutional Amendment. *Lancet* 2013;  
11 381(9884):2193-206.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Table 1 Characteristics of the participants by diabetes categories (n=18,856)

	Non-Diabetic N (%)	Pre-Diabetic N (%)	Diabetic N (%)	P-value
	13,598 (72.11)	2,057 (10.91)	3,201 (16.98)	
<b>Age (years)</b>				
20-30	2,772 (20.37)	218 (10.60)	176 (5.52)	<0.001
31-40	3,503 (25.74)	425 (20.66)	511 (16.01)	
41-50	3,802 (27.94)	654 (31.79)	1,033 (32.37)	
51-60	1,955 (14.37)	412 (20.03)	833 (26.10)	
61 & above	1,576 (11.58)	348 (16.92)	638 (19.99)	
<b>Gender</b>				
Male	7363 (54.15)	1099 (53.43)	1638 (51.17)	0.010
Female	6235 (45.85)	958 (46.57)	1563 (48.83)	
<b>Education</b>				
No formal education	9,853 (72.41)	1516 (73.70)	2,439 (76.43)	<0.001
Primary	1936 (14.23)	354 (17.21)	452 (14.16)	
Secondary	818 (6.01)	99 (4.81)	184 (5.77)	
Graduation	1001 (7.36)	88 (4.28)	116 (3.64)	
<b>Area</b>				
Urban	9,117 (67.00)	1,213 (58.97)	1,932 (60.55)	<0.001
Rural	4,491 (33.00)	844 (41.03)	1,259 (39.45)	
<b>Family History</b>				
Negative	10325 (75.93)	1210 (58.82)	1320 (41.24)	<0.001
Positive	3273 (24.07)	847 (41.18)	1881 (58.76)	
<b>Smoking</b>				
Never	12682 (93.26)	1893 (92.03)	2937 (91.75)	0.008
Ex-Smoker	275 (2.02)	49 (2.38)	91 (2.84)	
Current smoker	641 (4.71)	115 (5.59)	173 (5.40)	
<b>Systolic BP (mean <math>\pm</math>SD)</b>	124.98	128.17	130.77	0.020
<b>Diastolic BP (mean <math>\pm</math>SD)</b>	82.75	84.13	84.84	0.006
<b>BMI</b>				
Underweight (<18.5)	279 (2.05)	31 (1.51)	35 (1.09)	
Normal (18.5-<25)	5137 (37.78)	668 (32.47)	1019 (31.83)	<0.001
Overweight (25-<30)	5884 (43.27)	850 (41.32)	1288 (40.24)	
Obese1 (30-<35)	1844 (13.56)	396 (19.25)	621 (19.40)	
Obese 2 (35-<40)	372 (2.74)	83 (4.04)	178 (5.56)	
Obese 3 ( $\geq$ 40)	82 (0.60)	29 (1.41)	60 (1.87)	
<b>Waist circumference *</b>				
Normal Weight	6,787 (70.88)	645 (51.68)	1,142 (55.93)	
Over weight	1,676 (17.50)	285 (22.84)	357 (17.48)	<0.001
Obese	1,113 (11.62)	318 (25.48)	543 (26.59)	
<b>Waist to Hip ratio *</b>				
Normal Weight	3,219 (33.62)	394 (31.57)	658 (32.22)	
Over weight	5,528 (57.73)	768 (61.54)	1,171 (57.35)	
Obese	828 (8.65)	86 (6.89)	213 (10.43)	0.002

\* n for Waist circumference & waist to hip ratio is 12865

Table 2 Logistic regression analysis of the participant characteristics associated with having diabetes (HbA1c $\geq$ 6.5 % DCCT aligned /48 mmol/mol IFFC units) (n=18,856)

	Univariate OR (95% CI)	P-value	Multivariate OR (95% CI)	P-value
<b>Age</b>				
20-30	1		1	
31-40	2.21 (1.8, 2.6)	<0.001	2.03 (1.7, 2.4)	<0.001
41-50	3.93 (3.3,4.6)	<0.001	3.39 (2.9, 4.0)	<0.001
51-60	5.97 (5.0, 7.1)	<0.001	4.87 (4.1, 5.8)	<0.001
61 & above	5.63 (4.7, 6.7)	<0.001	4.93 (4.1, 6.0)	<0.001
<b>Gender</b>				
Male	1		1	
Female	1.12 (1.0,1.2)	0.003	1.04 (0.9, 1.1)	0.334
<b>Education</b>				
No formal education	2.02 (1.6,2.4)	<0.001	1.83 (1.5, 2.3)	<0.001
Primary	1.85 (1.49, 2.3)	<0.001	1.39 (1.1 , 1.8)	0.006
Secondary	1.89 (1.47,2.4)	<0.001	1.57 (1.2 , 2.0)	0.001
Graduation	1		1	
<b>Area</b>				
Urban	1		1	
Rural	1.26 (1.16, 1.34)	<0.001	1.08 (0.9, 1.2)	0.084
<b>Family History of diabetes</b>				
Negative	1		1	
Positive	3.98 (3.6,4.3)	<0.001	3.94 (3.6, 4.3)	<0.001
<b>Smoking</b>				
Never	1		1	
Ex- Smoker	1.39 (1.1, 1.8)	0.006	1.13 (0.9 , 1.5)	0.323
Current Smoker	1.13 (0.9,1.3)	0.14	1.06(0.9, 1.3)	0.571
<b>Systolic BP</b>	1.02 (1.021, 1.026)	<0.001	1.01 (1.01, 1.02)	<0.001
<b>Diastolic BP</b>	1.01 (1.01, 1.02)	<0.001	0.99 (0.9 , 1.0)	0.310
<b>BMI</b>				
Underweight (<18.5)	0.64 (0.4, 0.9)	0.001	0.71 (0.5, 1.0)	0.077
Normal (18.5-<25)	1		1	
Overweight (25-<30)	1.08 (0.9,1.2)	0.06	1.06 (0.9, 1.1)	0.182
Obese1 (30-<35)	1.57 (1.4,1.7)	<0.001	1.54 (1.3, 1.7)	<0.001
Obese 2 (35-<40)	2.22 (1.8,2.6)	<0.001	2.13 (1.7, 2.6)	<0.001
Obese 3 ( $\geq$ 40)	3.07 (2.2,4.2)	<0.001	2.44 (1.7, 3.5)	<0.001
<b>Waist circumference *</b>				
Normal Weight	1		1	
Over weight	1.18 (1.04, 1.34)	0.01	0.98 (0.8, 1.1)	0.774
Obese	2.46 (2.19, 2.77)	<0.001	1.86 (1.6, 2.2)	<0.001
<b>Waist to Hip Ratio *</b>				
Normal Weight	1		1	

1					
2					
3	Over weight	1.02 (0.92, 1.13)	0.40	0.8 (0.7, 0.9)	<0.001
4	Obese	1.27 (1.07, 1.51)	0.005	1.13 (0.9, 1.4)	0.205
5					
6	<hr/>				

7 \* n for WC & WHR is 12865. The following variables were included in the multivariate  
8 regression: Age, gender, education, residence area, family history of diabetes, smoking,  
9 systolic and diastolic blood pressure and BMI.

10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Table 3: Summary statistics for diabetes diagnosed by HbA1c compared to diabetes diagnosed by 2hrs OGTT (n=1,027)


		[95% Confidence Interval]		
Prevalence	Pr (A)	40.6%	37.6%	43.7%
Sensitivity	Pr (+ A)	84.7%	80.8%	88.0%
Specificity	Pr (- N)	87.2%	84.3%	89.8%
ROC area	(Sens. + Spec.) / 2	0.86	0.84	0.88
Likelihood ratio (+)	Pr (+ A) / Pr (+ N)	6.62	5.36	8.18
Likelihood ratio (-)	Pr (- A) / Pr (- N)	0.18	0.14	0.22
Odds ratio	LR (+) / LR (-)	37.62	26.34	53.73
Positive predictive value	Pr (A +)	81.9%	77.9%	85.4%
Negative predictive value	Pr (N -)	89.3%	86.5%	91.6%

ew only

1  
2  
3 Figure 1: Prevalence of diabetes (diagnosed by HbA1c $\geq$ 6.5 % DCCT aligned /48 mmol/mol  
4 IFFC units) by regions of Pakistan, age, gender, education, family history of diabetes,  
5 hypertension, waist circumference, waist to hip ratio and body mass index (n=18,856).  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only





Prevalence of diabetes (diagnosed by HbA1c ≥ 6.5 % DCCT aligned /48 mmol/mol IFFC units)

246x187mm (300 x 300 DPI)

# Reporting checklist for cross sectional study.

Based on the STROBE cross sectional guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the STROBE cross sectional reporting guidelines, and cite them as:

von Elm E, Altman DG, Egger M, Pocock SJ, Gotsche PC, Vandembroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

		Reporting Item	Page Number
Title	#1a	Indicate the study's design with a commonly used term in the title or the abstract	1
Abstract	#1b	Provide in the abstract an informative and balanced summary of what was done and what was found	3
Background / rationale	#2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	#3	State specific objectives, including any prespecified hypotheses	5
Study design	#4	Present key elements of study design early in the paper	6
Setting	#5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6
Eligibility criteria	#6a	Give the eligibility criteria, and the sources and methods of selection of participants.	6-7

1		#7	Clearly define all outcomes, exposures, predictors, potential	7
2			confounders, and effect modifiers. Give diagnostic criteria, if	
3			applicable	
4				
5				
6	Data sources /	#8	For each variable of interest give sources of data and details of	7-8
7	measurement		methods of assessment (measurement). Describe	
8			comparability of assessment methods if there is more than one	
9			group. Give information separately for for exposed and	
10			unexposed groups if applicable.	
11				
12				
13				
14	Bias	#9	Describe any efforts to address potential sources of bias	8
15				
16				
17	Study size	#10	Explain how the study size was arrived at	6
18				
19	Quantitative	#11	Explain how quantitative variables were handled in the	7
20	variables		analyses. If applicable, describe which groupings were chosen,	
21			and why	
22				
23				
24	Statistical	#12a	Describe all statistical methods, including those used to control	8
25	methods		for confounding	
26				
27				
28		#12b	Describe any methods used to examine subgroups and	8
29			interactions	
30				
31				
32		#12c	Explain how missing data were addressed	8
33				
34				
35		#12d	If applicable, describe analytical methods taking account of	8
36			sampling strategy	
37				
38				
39		#12e	Describe any sensitivity analyses	8
40				
41	Participants	#13a	Report numbers of individuals at each stage of study—eg	8-9
42			numbers potentially eligible, examined for eligibility, confirmed	
43			eligible, included in the study, completing follow-up, and	
44			analysed. Give information separately for for exposed and	
45			unexposed groups if applicable.	
46				
47				
48				
49		#13b	Give reasons for non-participation at each stage	8
50				
51				
52		#13c	Consider use of a flow diagram	6
53				
54	Descriptive data	#14a	Give characteristics of study participants (eg demographic,	8-9
55			clinical, social) and information on exposures and potential	
56			confounders. Give information separately for exposed and	
57			unexposed groups if applicable.	
58				
59				
60				

1		#14b	Indicate number of participants with missing data for each	8-9
2			variable of interest	
3				
4				
5	Outcome data	#15	Report numbers of outcome events or summary measures.	9
6			Give information separately for exposed and unexposed	
7			groups if applicable.	
8				
9				
10	Main results	#16a	Give unadjusted estimates and, if applicable, confounder-	9
11			adjusted estimates and their precision (eg, 95% confidence	
12			interval). Make clear which confounders were adjusted for and	
13			why they were included	
14				
15				
16				
17		#16b	Report category boundaries when continuous variables were	9
18			categorized	
19				
20				
21		#16c	If relevant, consider translating estimates of relative risk into	9
22			absolute risk for a meaningful time period	
23				
24	Other analyses	#17	Report other analyses done—e.g., analyses of subgroups and	9
25			interactions, and sensitivity analyses	
26				
27				
28	Key results	#18	Summarise key results with reference to study objectives	9
29				
30				
31	Limitations	#19	Discuss limitations of the study, taking into account sources of	11
32			potential bias or imprecision. Discuss both direction and	
33			magnitude of any potential bias.	
34				
35				
36	Interpretation	#20	Give a cautious overall interpretation considering objectives,	11
37			limitations, multiplicity of analyses, results from similar studies,	
38			and other relevant evidence.	
39				
40				
41	Generalisability	#21	Discuss the generalisability (external validity) of the study	11
42			results	
43				
44				
45	Funding	#22	Give the source of funding and the role of the funders for the	12
46			present study and, if applicable, for the original study on which	
47			the present article is based	
48				
49				

The STROBE checklist is distributed under the terms of the Creative Commons Attribution License CC-BY. This checklist was completed on 04. July 2018 using <http://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)

# BMJ Open

## DIABETES PREVALENCE SURVEY OF PAKISTAN (DPS- PAK): Prevalence of type 2 Diabetes Mellitus and pre-diabetes using HbA1c: A population-based survey from Pakistan

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-025300.R2
Article Type:	Research
Date Submitted by the Author:	18-Dec-2018
Complete List of Authors:	Aamir, Azizul Hasan; Hayatabad Medical Complex, Diabetes & Endocrinology & metabolic diseases Ul-Haq, Zia; Khyber Medical University, Institute of Public Health & Social Sciences; University of Glasgow Institute of Health and Wellbeing, Public Health Mahar, Saeed ; National Institute of Cardiovascular Diseases, Endocrinology Qureshi, Faisal; Al-Khaliq Hospital, Multan, Endocrinology Ahmad, Ibrar; Lady Reading Hospital, Endocrinology ward Jawa, Ali; Pakistan Institute of Medical Sciences, Endocrinology Sheikh, Aisha ; Aga Khan University, Endocrinology Raza, Abbas; Shaukat Khanum Memorial Cancer Hospital and Research Centre, Endocrinology Fazid, Sheraz; Khyber Medical University, Institute of Public Health & Social Sciences Jadoon, Zahid; Hayatabad Medical Complex Department of Ophthalmology, Epidemiology Ishtiaq, Osama; Shifa College of Medicine, Endocrinology Safdar, Nauman; Social and health inequalities Network, Social work Afridi, Hussain; Hayatabad Medical Complex, Department of Diabetes, Endocrinology and Metabolic Diseases Heald, Adrian; Leighton Hospital, Medicine
<b>Primary Subject Heading</b>:	Diabetes and endocrinology
Secondary Subject Heading:	Epidemiology
Keywords:	Type 2 Diabetes Mellitus, diabetes, HbA1c, Pakistan, pre-diabetes, Prevalence

SCHOLARONE™  
Manuscripts

**Title Page:****DIABETES PREVALENCE SURVEY OF PAKISTAN (DPS- PAK):  
Prevalence of type 2 Diabetes Mellitus and pre-diabetes using HbA1c: A  
population-based survey from Pakistan**

AzizulHasanAamir<sup>1</sup>, Zia Ul-Haq<sup>2,3</sup>, Saeed A. Mahar<sup>4</sup>, Faisal Masood Qureshi<sup>5</sup>, Ibrar Ahmad<sup>6</sup>, Ali Jawa<sup>7</sup>, Aisha Sheikh<sup>8</sup>, Abbas Raza<sup>9</sup>, Sheraz Fazid<sup>2</sup>, Zahid Jadoon<sup>10</sup>, Osama Ishtiaq<sup>11</sup>, Nauman Safdar<sup>12</sup>, Hussain Afridi<sup>1</sup>, Adrian H. Heald<sup>13</sup>

<sup>1</sup> Department of Diabetes, Endocrinology and Metabolic Diseases, Hayatabad Medical Complex, Peshawar, Khyber Pakhtunkhwa, Pakistan

<sup>2</sup> Institute of Public Health & Social Sciences, Khyber Medical University, Peshawar, KP, Pakistan

<sup>3</sup> Institute of Health and Wellbeing, University of Glasgow, Glasgow G12 8RZ, UK

<sup>4</sup> National Institute of cardiovascular diseases, Karachi

<sup>5</sup> Al-Khaliq Hospital, Multan.

<sup>6</sup> Lady Reading hospital, Peshawar.

<sup>7</sup> Pakistan Institute of medical sciences, Islamabad.

<sup>8</sup> Aga Khan University Hospital, Karachi.

<sup>9</sup> Shaukat Khanum Hospital, Lahore.

<sup>10</sup> Hayatabad Medical Complex, Peshawar.

<sup>11</sup> Shifa International Hospital, Islamabad.

<sup>12</sup> Social and Health Inequalities Network, Islamabad.

<sup>13</sup> The school of medicine and Manchester academic sciences centre, University of Manchester, Manchester, United Kingdom.

1. AzizulHasanAamir: [drahaamir@gmail.com](mailto:drahaamir@gmail.com), MBBS, MRCP, FRCP, FACE
2. ZiaUl-Haq: [drzia@kmu.edu.pk](mailto:drzia@kmu.edu.pk), MBBS, MPH, PhD
3. Saeed A. Mahar: [saeedamahar@yahoo.com](mailto:saeedamahar@yahoo.com). FRCP
4. Faisal Qureshi: [f-qureshi@hotmail.com](mailto:f-qureshi@hotmail.com). FACE
5. Ibrar Ahmed: [ibrar2127@hotmail.com](mailto:ibrar2127@hotmail.com). FCPS
6. Ali Jawa: [alijawa@gmail.com](mailto:alijawa@gmail.com). FACE
7. Aisha Shiekh: [aisha.sheikh@aku.edu](mailto:aisha.sheikh@aku.edu). FCPS
8. Abbas Raza: [sabbasraza@hotmail.com](mailto:sabbasraza@hotmail.com). FACE
9. Osama Ishtiaq: [docosama@gmail.com](mailto:docosama@gmail.com). FCPS
10. SherazFazid: [sherazvs@gmail.com](mailto:sherazvs@gmail.com) PhD Scholar, MPH
11. ZahidJadoon: [zahid@pico.org.pk](mailto:zahid@pico.org.pk). MSc
12. NaumanSafdar: [safdar.nauman@gmail.com](mailto:safdar.nauman@gmail.com). PhD
13. HussainAfridi: [mhussainafr@gmail.com](mailto:mhussainafr@gmail.com). FCPS
14. Adrian H. Heald: [adrian.heald@manchester.ac.uk](mailto:adrian.heald@manchester.ac.uk). FRCP

1  
2  
3 Correspondence to:  
4

5 Prof.AzizulHasanAamir

6 Head of the Department of Diabetes, Endocrinology and Metabolic Diseases

7 Hayatabad Medical Complex

8 Phase 5, Hayatabad, Peshawar, Pakistan

9 e-mail:drahaamir@gmail.com

10 Tel: +92 -91- 921-7794  
11  
12  
13  
14  
15

16 Word count (main text) 3483

17 Figures 01

18 Tables 03  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

### Objectives

We conducted a Pakistan-wide community-based survey on the prevalence of type-2 diabetes using HbA1c as the screening test. The aim was to estimate diabetes prevalence across different demographic groups as well as all regions of Pakistan.

### Design, settings and participants

Multi-staged stratified cluster sampling was used for the representative selection of people aged  $\geq 20$  years, residing in 378 sampled clusters of 16 randomly selected districts, in this cross sectional study. Eligible participants had blood drawn for HbA1c analyses at field clinics near to their homes. The oral glucose tolerance test (OGTT) was conducted on a subsample of the participants. Overall and stratified prevalence of type-2 diabetes and its association with risk factors were estimated using logistic regression models.

### Main outcome measures

Prevalence of pre-diabetes and type 2 diabetes

### Results

Of 18,856 eligible participants the prevalence of pre-diabetes was 10.91% (95% CI 10.46, 11.36,  $n=2,057$ ) and type-2 diabetes was 16.98% (95%CI 16.44, 17.51,  $n=3,201$ ). Overall, the mean HbA1c level was 5.62% (SD 1.96), and among newly diagnosed was 8.56% (SD 2.08). The prevalence was highest in age 51-60 years (26.03%,  $p<0.001$ ), no formal education (17.66%,  $p<0.001$ ), class-3 obese (35.09%,  $p<0.001$ ), family history (31.29%,  $p<0.001$ ) and female (17.80%,  $p=0.009$ ). On multivariate analysis, there was a significant association between type-2 diabetes and; older age, increase in BMI and central obesity, positive family history, and having hypertension and an inverse relation with education as a categorical variable. On a subsample ( $n=1,027$ ), summary statistics for diagnosis of diabetes on HbA1c showed a sensitivity of 84.7%, specificity of 87.2%, and ROC area 0.86, compared to OGTT.

### Conclusions

The prevalence of type-2 diabetes and pre-diabetes is much higher than previously thought in Pakistan. Comprehensive strategies need to be developed to incorporate screening, prevention and treatment of type-2 diabetes at a community level.

### Key words (mesh terms):

Type 2 Diabetes Mellitus, diabetes, Prevalence, HbA1c, OGTT, obesity, pre-diabetes, Pakistan



## Strength and limitations of this study

### Strengths:

Our study has the strength that we carried out HbA1c on all participants and OGTT on a subsample.

Furthermore this is the largest ever national prevalence study of type-2 diabetes mellitus from Pakistan and the first community based national study to use HbA1c as the diagnostic tool.

### Limitations:

The relatively low number (n=1,027) of 75g OGTT. Nevertheless the specificity and sensitivity of HbA1c versus OGTT was good.

We had to exclude 16% of recruited participants because of anaemia.

peer review only

## Background:

Type 2 Diabetes Mellitus is one of the most common public health issues worldwide and its incidence is on the rise particularly in middle and low-income countries[1]. When associated with complications, type-2 diabetes can have a profound impact on the person with consequences also for the society as a whole. Diabetes was previously thought to be a disease of the affluent and mostly prevalent in urban areas but due to urbanization, change in nutrition and a more sedentary lifestyle for many people, it has affected developing nations, including Pakistan[2].

Pakistan is a South Asian country with an area of 796,095 km<sup>2</sup> and a population of 207.7 million people[3]. In terms of population, Pakistan is the 6<sup>th</sup> most populous country and is the 36<sup>th</sup> largest country by geographical area in the world. Before 2018, the only previous national diabetes survey in Pakistan in 1999 (published in 2007), reported the prevalence of type-2 diabetes as 11% using the Oral Glucose Tolerance Test (OGTT)[4 5]. Part of the same survey separately reported the prevalence of type-2 diabetes in different provinces of Pakistan[4 6-8]. The International Diabetes Federation (IDF) reported in its Atlas 20 the prevalence for Pakistan to be 6.8%, aged 20-79[9], but health care professionals with local insight always believed this to be an underestimate. Subsequently there were conflicting findings with prevalence ranges from 7.2%-19.21% in different regions of the country[5].

The American Diabetes Association (ADA) criteria for the diagnosis of diabetes require either fasting plasma glucose (FPG) or 75gm OGTT which is time-consuming, requires fasting and may not always be reproducible[10 11]. In 2009, the International Expert committee on diabetes proposed new diagnostic criteria based on Glycated Haemoglobin (HbA1c), which captures chronic glucose exposure[12]. The proposed diagnostic threshold of 6.5% (48mmol/mol) was based on retinopathy risk at different levels of HbA1c as was the case with FPG and OGTT. This report was followed by a recommendation from the ADA that an HbA1c level of 6.5% (48mmol/mol) be used as the diagnostic cut-off for the diagnoses of diabetes (this has not been validated in Pakistan)[13].

A previous national level type-2 diabetes survey was conducted in 1999 with a sample size of 5433 using OGTT. In the study described in this paper, we investigated the prevalence of type-2 diabetes (using the HbA1c test) and its distribution across gender, age, rural and urban, education, Body Mass Index (BMI) WHO and Asian cut-offs, family history, smoking and blood pressure among a large sample across Pakistan, aged 20 years and above. A subsample was tested to explore the diagnostic accuracy of HbA1c for diagnosis of type-2 diabetes, compared to the 2-hour OGTT.

## Methods:

The Department of Diabetes, Endocrine and Metabolic Diseases, Hayatabad and Department of Health, Government of Khyber Pakhtunkhwa, Pakistan with technical support from Institute of Public Health, Khyber Medical University Peshawar Pakistan, University of Manchester UK and Pakistan Endocrine Society conducted a nationwide cross-sectional study for the prevalence of type-2 diabetes starting from April 2017 to November 2017. Three teams of trained field workers under the supervision of epidemiologists collected basic demographic data and blood samples from the selected sample. The study sample was selected based on a stratified two-stage cluster design, including all metropolitan cities of Pakistan and randomly selected districts (both rural and urban settings) within each province. The sample included districts from central and south of Punjab province (Lahore, Multan, Bahawalpur, Rahim Yar Khan), interior Sindh (Larkana, Dadoo, Sukkur), central Sindh (Karachi), northern Khyber Pakhtunkhwa (KP) (Haripur), central (Peshawar) and southern KP province (Karak), Baluchistan province (Quetta), capital territory (Rawalpindi-Islamabad), Azad Jammu Kashmir (Muzaffarabad), Frontier Region Peshawar and the Khyber Agency in Federal Administered Tribal Area (FATA).

### Sample size and sampling methodology:

The sample size was estimated for the provinces of the country based on recent census results. The sample size was estimated based on an expected prevalence of 12% with 20% relative precision and a design effect of 2[6]. For a 95% confidence interval and an additional adjustment of 32% for non-responders, keeping in view an exclusion rate due to an expected high prevalence of anaemia, the sample size was 4407 approximated to 4500 in order to have 50 subjects from each cluster. All provinces were included as was the Federal territory. AJK and FATA were considered as one province for the survey purpose because of their small size of the population. The number of eligible subjects was  $4500 \times 5 = 22500$ .

Three districts were randomly selected from each province and the sample size was equally divided on these districts. Fifteen hundred subjects (30 clusters, 50 subjects per cluster) were examined in each district. The sample was proportionately divided amongst urban and rural areas. Probability proportionate to size (PPS) method was used to select clusters from villages in the rural settings of the district. In urban settings, clusters were selected from charges and circles (defined in the national census) using the PPS method.

Maps were obtained from the census office of selected villages/charges/circles (V/C/C). Maps of each V/C/C was divided into equal segments such that each segment had approximately 50 persons 20 years and above. One segment was randomly selected and every house within the segment was included. All persons 20 and above living in that house were examined until the 50 number was reached. Any person who was absent on the day of survey until evening, was terminally ill, who fitted into exclusion criteria or who refused were marked as non-responders.

1  
2  
3 Ethical approval was granted from Khyber Medical University ethical board (DIR/KMU-  
4 EB/SP/000395). Conditions that may affect HbA1c including anaemic subjects with  
5 haemoglobin less than 12gm/dl in women and less than 14 gm/dl in men, self-reported renal and  
6 hepatic dysfunction, recent blood transfusion, and use of erythropoietin, age below 20 years or  
7 refusal to participate resulted in exclusion. Face to face interview was conducted at the  
8 participant's home to collect information on demographics (including age, gender, residential  
9 area, formal education, family history of diabetes, and smoking status) using a paper  
10 questionnaire in local languages. Eligible participants were called to a central point established in  
11 the *hujra* (local public gathering place) where their haemoglobin was tested using the Mission  
12 Plus Haemoglobin Meter (reflectance photometer technique) Acon Laboratories, Inc., San Diego  
13 (coefficient of variance CV:3%). Blood pressure was measured using an automated digital blood  
14 pressure monitor Konfort Model AS-351 in the lying position with the average of three readings  
15 was recorded. Weight in kilograms and height in meters was recorded and used to calculate Body  
16 Mass Index.  
17  
18  
19  
20  
21  
22

23 Diabetes status was assessed for HbA1c on blood samples using the National Glycohemoglobin  
24 Standardization Program (NGSP) certified FIA 8000 immunoassay analyser (lateral flow  
25 chromatography colloidal gold) traceable to diabetes control and complication trial (DCCT)  
26 reference method (CV: 3-5%). To compare the results from HbA1c, 2-hour OGTT was  
27 conducted on a random sample of participants from all clusters (n=1,027) in the specified  
28 standard laboratory using Cobas C311 Roche Diagnostics, Mannheim, Germany. Participants  
29 were given vouchers for free OGTT test within 7 days in a nearby laboratory using Cobas C311  
30 Roche Diagnostics.  
31  
32  
33

### 34 **Definitions:**

35 Age was categorised into six groups: 20-30, 31-40, 41-50, 51-60 and 61 and above years. The  
36 residential area was classified as urban and rural based on local government criteria. Formal  
37 education status was self-reported was categorized as no formal education, primary, secondary  
38 and graduation/post-graduation. BMI was categorised on WHO criteria into underweight (<18.5  
39 kg/m<sup>2</sup>), normal weight (18.5-24.9 kg/m<sup>2</sup>), overweight (25-29.9 kg/m<sup>2</sup>), class I obese (30-34.9  
40 kg/m<sup>2</sup>), class II obese (35-39.9 kg/m<sup>2</sup>), and class III obese (>40 kg/m<sup>2</sup>)(World Health  
41 Organization., 1995). Waist Circumference (WC) was categorized into normal-weight (0-93.99),  
42 overweight (94-102) and obese (102 & above).Waist to hip ratio (WHR) was categorized into  
43 normal-weight (0-0.89), overweight (0.90-0.99) and obese (1 & above)[14].The family history of  
44 diabetes was categorised to negative or positive on the basis of the participant's self-reporting,  
45 based on physician's diagnoses. Smoking status was categorized as never, ex or current smoker.  
46 Systolic and diastolic blood pressure was measured using a standard procedure and Hypertension  
47 was defined on a blood pressure measurement of  $\geq 140/90$  mmHg or anti-hypertensive  
48 medication. Patients were considered as known type-2 diabetes based on self-reporting and or  
49 being on dietary or exercise advice, oral anti-diabetes medications or insulin. This self-reported  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

group of patients could either be on single medications or on different drug combinations or diet and exercise therapy.

Type 2 diabetes was diagnosed based on HbA1c results in keeping with the WHO levels for non diabetes (<5.69 % DCCT aligned/38 mmol/mol IFFC units), pre-diabetes (5.7-6.49% DCCT aligned/ 39-47mmol/mol IFFC units), diabetes ( $\geq 6.5$  % DCCT aligned /48 mmol/mol IFFC units). For univariate and multivariate logistic regression models, diabetes was dichotomized to No (0; HbA1c level <6.5) and Yes (1; HbA1c level  $\geq 6.5$ ).

### **Statistical Analyses:**

Differences in the characteristics of participants by diabetes category were analysed using the  $\chi^2$  test for categorical data and ANOVA for continuous data. We examined the association between diabetes and risk factors i.e., age, gender, residence area, education, BMI, family history of diabetes, smoking, systolic and diastolic blood pressure, using univariate and multivariate logistic regression models. Multivariate regression analysis included all these variables.

Taking OGTT as the standard on a sub subsample, the diagnostic accuracy summary statistics (sensitivity, specificity, ROC area, positive and negative predictive value) for the diagnosis of diabetes using HbA1c were determined. All statistical analyses were performed using Stata version 14 (StataCorp, College Station, Texas). Statistical significance was defined as  $p < 0.05$  and analysis were adjusted for the cluster design.

### **Patient and Public Involvement statement:**

Patients were not involved in the study conception or design. There was consultation with interested representative public bodies but not with individual members of the public.

### **Results:**

Of the 22,500 participants, 3,644 (16%) were anaemic and therefore excluded from the study. Out of the remaining, 18,856 participants aged 20 and above, were examined from 378 clusters of which 216 were rural generating a response rate of 84%. The mean age was 45.23 years (standard deviation [SD] 13.97 years). Most of the participants 10,116 (53.55%) were men, 4,148 (21.96%) were hypertensive and those with higher blood pressure were advised to check their blood pressure by visiting their doctors. Majority of the participants, 13,834 (73.24%), had no formal education and 1,209 (6.40%) had graduated. 6,010 (31.81%) had a family history of type-2 diabetes. Overall on WHO cut-off 345 (1.83%) were underweight, 6,839 (36.20%) normal-weight, 8,038 (42.55%) overweight, 2,864 (15.16%) class I obese, 633 (3.35%) class II obese, and 172 (0.91%) class III obese. On waist circumference (WC) cut-off (n=12865) 8,574 (66.64%) were normal-weight, 2,318 (18.02%) were overweight and 1,974 (15.34%) were obese. On central obesity cut-off (WHR, n=12865) 4,271 (33.20%) were normal weight, 7,467

(58.04%) were overweight and 1,127 (8.76%) were obese. Mean systolic blood pressure was 126.30mmHg (SD 14.2) and diastolic blood pressure was 83.24mmHg (SD 10.2).

Overall, 3,201 subjects (16.98%, 95%CI 16.44, 17.51) had type-2 diabetes based on HbA1c screening. Pre-diabetes was present in 2,057 subjects 10.91% (95% CI 10.46, 11.36). The mean HbA1c level of the entire cohort (n=18856) was 5.62% (SD 1.96), among known type-2 diabetes (n=2179) had 8.68% (SD 2.70) and newly diagnosed type-2 diabetes (n=1577) had 8.56% (SD2.08). The prevalence of diabetes differed significantly by age, education, BMI, WC, WHR, family history, and blood pressure (Table 1) (Figure 1). The prevalence of diabetes was highest in age 51-60 years (26.03%, p<0.001), no formal education (17.73%, p<0.001), class 3 obese (32.19%, p<0.001), and with a positive family history of diabetes (31.34%, p<0.001) (Figure 1). There were also statistically significant differences in diabetes prevalence by gender (female 17.85%, p=0.01), rural/urban (rural 19.09%, p<0.001) and that smoking status (p=0.008).

On univariate logistic regression analysis, there was a significant association between age, gender, education, BMI category, family history, blood pressure and type 2 diabetes (p<0.005) (Table 2).

On multivariate logistic regression, there was significantly higher risk of diabetes with age (adjusted Odds Ratio [OR] 2.03, 3.39, 4.87 and 4.93, p< 0.001, aged 31-40 years, 41-50 years, 51-60 years and 61 years and above respectively, compared to age 20-30 years), BMI (adjusted OR 1.54, 2.13, 2.44, p-value <0.001 for class 1, class II and class III obese respectively, compared to normal weight) with evidence of a dose-response relationship. Similarly, there was a significantly higher risk of diabetes with lower educational attainment (adjusted OR 1.83, 1.39, 1.57, no formal education, primary and secondary education respectively, compared to graduates). There was a significantly higher risk of diabetes in people with a positive family history (adjusted OR 3.94, 95% CI 3.6, 4.3 p<0.001), than with no family history of diabetes. There was no significant association with smoking and rural/urban area.

Among 1,029 participants who were tested for 2-hour OGTT, in addition to HbA1c, the mean 2-hour OGTT was 200.26 (SD 91.7), and the median was 178 (inter-quartile range 100). Taking the OGTT as the gold standard, HbA1c recommended cut-off for diabetes showed a sensitivity of 84.7% (95% CI 80.8, 88) and Specificity of 87.2% (95% CI 84.3, 89.8%), ROC area 0.86 (95% CI 0.84, 0.88), positive predictive value 81.9% (95% CI 77.9, 85.4), and negative predictive value 89.3 (86.5, 91.6) (Table 3).

## Discussion:

This is the first community based national study done in the region based on HbA1c and with the eligible 18,856 subjects from Pakistan this is the largest study to date from that country. The prevalence of type-2 diabetes across Pakistan was 16.98% (95%CI 16.44, 17.51) and pre-diabetes was 10.91% (95% CI 10.46, 11.36). This is higher than found in the only previous national survey conducted in 1999 (n=5433) using OGTT. There was a significantly higher risk of type-2 diabetes with increasing systolic blood pressure, age, BMI, WC, WHR with evidence of a dose-response relationship. Similarly, there was a significant inverse relationship of type-2 diabetes with the level of formal education. The risk of diabetes increased 2.68 times with a prior family history. The HbA1c level had good sensitivity and specificity level for the diagnosis of type-2 diabetes compared to a 2-hour OGTT level and is therefore valid in community settings for screening purposes.

We have noted the findings of Basit et al[15]. The methodology for that study was based on 75g OGTT for glucose handling as opposed to HbA1c used in our study. While the prevalence of diabetes and pre-diabetes is different in the two studies, the point that both studies make is that both diabetes and pre-diabetes are much more prevalent than previously thought.

The previous national prevalence study conducted in 1999 used OGTT where almost 80% of the subjects were women as the test was conducted in the morning time [4]. In contrast, our study screening was done all through the day so that working men had an equal opportunity to be part of the study. They constituted 50% of the study population. OGTT is the gold standard for the type 2 diabetes screening but because of the length of time which is required for the test and the fact that the person must be fasting, it is very difficult to perform in many community settings in Pakistan. Also, the high temperatures in South Asia make it difficult to keep the sample stable for transportation to the laboratory. To minimize the effect of temperature and transportation errors on HbA1c, all tests were conducted in the field.

Recently a study carried out in 15 states of India showed that the prevalence of type-2 diabetes ranged between 4%-13.6% and showed variation due to age, male sex, obesity and family history using capillary FBG for diagnosis[16]. A capillary blood sample for epidemiological studies is not an ideal test but the authors acknowledged the logistic hindrance in carrying out venous sample test in the field. A high prevalence in another Indian study was reported ranging from 12.1-14% for diabetes using OGTT on a sample size of 11,216 subjects[17].

A study conducted in Bangladesh was based on capillary fasting level found a prevalence of type-2 diabetes of 4.3% in a rural setting[18]. Risk factors were positive family history for diabetes, age, high BMI and low socio-economic status, similar to our study. Although these are geographically distant areas, the risk factors showed commonality in both studies, which suggests these risk factors as an important tool for mass screening[19].

1  
2  
3 The age sex-standardized prevalence of type-2 diabetes for Sri Lankans was 10.3% based on  
4 OGTT[20]. The risk factors were almost the same as seen in our study. The investigators found  
5 dysglycaemia in almost 21.8% participants and predicted that this would lead to a higher  
6 prevalence of T2DM in the years to come. Another study from Sri Lanka indicated a prevalence  
7 of 14.2% based on FBG[21]. FBG as well as, OGTT blood glucose levels, may not be  
8 reproducible in an epidemiological survey if the individual are changing lifestyle in terms of diet  
9 and exercise. The use of HbA1c in our study makes our study more scientific, addressing issues  
10 pertaining to sampling errors in the local environment.  
11  
12  
13  
14

15 The Asian population is known to have a significantly higher risk of developing diabetes and its  
16 related complications as predicted by IDF projections[1]. It makes it very important from a  
17 public health point of view to identify high-risk individuals at an early stage. The HbA1c test has  
18 been used successfully in community settings[22]. A national health survey New Zealand in  
19 2008-9 used HbA1c to identify high-risk individuals with diabetes and pre-diabetes[23]. A study  
20 in Japan revealed that a combination of tests including FBG and HbA1c yields more diabetes  
21 cases compared to any of these tests alone[24].  
22  
23  
24  
25

26 WHO experts have accepted HbA1c as a diagnostic tool provided quality assurance tests are in  
27 place and there are no conditions present, which preclude its accurate measurement. The New  
28 Zealand Society for the study of Diabetes and the Australian Diabetes Society have already  
29 endorsed HbA1c as a test for the diagnosis of diabetes[25 26]. Recently a prevalence study done  
30 in Korea concluded that FBG testing results in underestimation of diabetes and pre-diabetes[27].  
31 This study suggested the use of standardized HbA1c as a diagnostic tool for diagnosis of type-2  
32 diabetes.  
33  
34  
35  
36

37 We found that HbA1c level had a good sensitivity and specificity level for diagnoses of diabetes  
38 compared to the OGTT. HbA1c has the advantage of being a simple test and less time  
39 consuming, making it an ideal test for community surveys in our populations. In Pakistan, as  
40 there is no effective primary care (general/ family practice) structure most of the population does  
41 not undergo primary screening for diabetes. Sometimes as the diagnosis is made, people  
42 may present to tertiary care with complications.  
43  
44  
45

46 Thus there is a strong case for applying HbA1c for screening purposes in the community setting.  
47 There will always be an argument about the cost of the test and whether this to be used for  
48 screening purposes. However particularly those at social disadvantage need to be undergo  
49 screening to improve the diagnosis timely treatment of diabetes[28]. Early diagnosis will also  
50 reduce diabetes-related complications.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Strengths and limitations:**

Our study has the strength that we carried out HbA1c on all participants and OGTT on a subsample. Furthermore this is the largest ever national prevalence study of type-2 diabetes mellitus from Pakistan and the first community based national study to use HbA1c as the diagnostic tool.

Limitations are the relatively low number (n=1,027) of 75gOGTT. Nevertheless the specificity and sensitivity of HbA1c vs OGTT was good. We had to exclude 16% of recruited participants because of anaemia.

The central Government of Pakistan has developed and agreed on Non- Communicable Diseases (NCD) National Action Plan including diabetes however, it was never implemented. After the 18<sup>th</sup> Amendment in the constitution of Pakistan in 2010, provinces are responsible for making and implementing their own health policies and the role of central Government is limited to coordination among the different provinces[29]. There is a dire need that based on the agreed NCD National Action Plan each province should build their capacity for implementing it at both primary and secondary level. Pakistan is a signatory to the Sustainable Development Goals 2030 document which outlines among its goals, increasing access to universal health coverage, increasing coverage of health insurance program and adopting a family medicine approach. When implemented, these will not only be major steps towards prevention and control of diabetes but all non-communicable diseases.

**Conclusions:**

This national diabetes prevalence study is the first one in the region using HbA1c identified a huge population of type-2 diabetes and pre-diabetes group. The prevalence of type-2 diabetes and pre-diabetes is much higher than previously thought in Pakistan. Comprehensive strategies need to be developed to incorporate screening, prevention and treatment of type-2 diabetes at community level. Those who are obese, with no formal education, older, family history of diabetes and hypertensive merit close attention and timely intervention.

HbA1c is an applicable test in community settings in developing countries and it has a good correlation with 2-hour OGTT. Our findings have the potential to influence policy in developing countries and induce a shift towards the prevention and control of non-communicable diseases.

1  
2  
3 **Acknowledgements** Khyber Pakhtunkhwa Government of Pakistan and field staff for supporting  
4 survey the Pakistan Endocrine Society for technical and logistic support in this survey,  
5 The Institute of Public Health, Prof Dr Zia and his team particularly Dr Basharat Hussain Shah at  
6 Khyber Medical University for statistical support and the University of Manchester for help in  
7 data analysis and in reviewing the manuscript.  
8  
9

10 **Contributors** AHA, ZUH conceived the study. AHA, SM, FQ, AS, AJ, OI, AR, IA, HA  
11 collected the data. ZJ, NS study design and data monitoring. ZUH, AHA, SF, AH, conducted the  
12 analysis and wrote the manuscript. All authors reviewed the manuscript. AHA and ZUH  
13 contributed equally.  
14

15  
16 **Funding Statement** This research received no specific grant from any funding agency in the  
17 public, commercial or not-for-profit sectors.  
18

19 **Competing interest** None declared  
20

21  
22 **Patient Consent** Written informed consent granted. The data is fully anonymised and neither the  
23 patient nor anyone else could identify the patient.  
24

25  
26 **Ethical approval** The ethical approval was granted from the Khyber Medical University ethical  
27 board (DIR/KMU-EB/SP/000395).  
28

29 **Data sharing statement** No additional data are available  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**References:**

1. Cho NH, Shaw JE, Karuranga S, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. *Diabetes Res Clin Pract* 2018; 138: 271-281.
2. Roglic G, Unwin N, Faurholt-Damsgaard T, Bennett PH, Bennett Ph, Faurholt-Damsgaard T, Mathers C, et al. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. *Diabetes Care* 2015; 0149-5992.
3. Provisional summary results of 6th population and housing census-2017. Secondary Provisional summary results of 6th population and housing census-2017; <http://www.pbs.gov.pk/content/provisional-summary-results-6th-population-and-housing-census-2017-0> (accessed July 2018).
4. Shera AS, Jawad F, Faurholt-Damsgaard T, Maqsood A. Prevalence of diabetes in Pakistan. *Diabetes Res Clin Pract* 2007;76(2):219-22
5. Meo SA, Zia I, Bukhari IA, et al. Type 2 diabetes mellitus in Pakistan: Current prevalence and future forecast. *JPMA* 2016;66(12):1637-42.
6. Shera AS, Rafique G, Faurholt-Damsgaard T, Khwaja IA, Khwaja Ia, Faurholt-Damsgaard T, Baqai S, et al. Pakistan National Diabetes Survey prevalence of glucose intolerance and associated factors in North West at Frontier Province (NWFP) of Pakistan. *J Pak Med Assoc* 1999;49 (9): 206-11.
7. Shera AS, Rafique G, Faurholt-Damsgaard T, Khawaja IA, Khawaja Ia, Faurholt-Damsgaard T, Baqai S, et al. Pakistan National Diabetes Survey: prevalence of glucose intolerance and associated factors in Baluchistan province. *Diab Res Clin Pra* 1999;49-58.
8. Shera AS, Rafique G, Faurholt-Damsgaard T, Khwaja IA, Khwaja Ia, Faurholt-Damsgaard T, Ara J, et al. Pakistan national diabetes survey: prevalence of glucose intolerance and associated factors in Shikarpur, Sindh Province. *Diab Med* 1995; 12 (12): 1116-21.
9. Whiting DR, Guariguata L, Weil C, et al. IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. *Diab Res Clin Pra* 2011;94(3):311-21.
10. American Diabetes A. Diagnosis and classification of diabetes mellitus. *Diabetes Care* 2014; 37:S81-S90.
11. Klein BE. Overview of epidemiologic studies of diabetic retinopathy. *Ophth Epid* 2007; 14 (4)-179-83.
12. The International Expert C. International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes. *Diabetes Care* 2009;32(7):1327-34.
13. American Diabetes A. Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 2010;33(Suppl 1):S62-S69.

14. Ahmad N, Adam SIM, Nawari AM, et al. Abdominal Obesity Indicators: Waist Circumference or Waist-to-hip Ratio in Malaysian Adults Population. *Int J of Prev Med* 2016;7:82.
15. Basit A, Fawwad A, Qureshi H, et al. Prevalence of diabetes, pre diabetes and associated risk factors: second National Diabetes Survey of Pakistan (NDSF), 2016-2017. *BMJ Open* 2018;5;8(8):e020961.
16. Anjana RM, Deepa M, Pradeepa R, et al. Prevalence of diabetes and prediabetes in 15 states of India: results from the ICMR-INDIAB population-based cross-sectional study. *Lanc Diab End* 2017; 5(8):585-96.
17. Ramachandran A, Snehalatha C Fau - Kapur A, Kapur A Fau - Vijay V, et al. High prevalence of diabetes and impaired glucose tolerance in India: National Urban Diabetes Survey. *Diabetologia* 2001;44(9):1094-101.
18. Sayeed MA, Mahtab H Fau - Akter Khanam P, Akter Khanam P Fau - Abdul Latif Z, et al. Diabetes and impaired fasting glycemia in a rural population of Bangladesh. *Diabetes Care*; 2003; 26(4):1034-9.
19. McKeigue PM, Marmot Mg Fau - Syndercombe Court YD, Syndercombe Court Yd Fau - Cottier DE, et al. Diabetes, hyperinsulinaemia, and coronary risk factors in Bangladeshis in east London. *Br Heart J* 1988; 60(5)390-96.
20. Katulanda P, Constantine Gr Fau - Mahesh JG, Mahesh Jg Fau - Sheriff R, et al. Prevalence and projections of diabetes and pre-diabetes in adults in Sri Lanka--Sri Lanka Diabetes, Cardiovascular Study (SLDCS). *Diabet Med* 2008; 25(9) 1062-9.
21. Wijewardene K, Mohideen Mr Fau - Mendis S, Mendis S Fau - Fernando DS, et al. Prevalence of hypertension, diabetes and obesity: baseline findings of a population based survey in four provinces in Sri Lanka. *Ceylon Med J* 2005; 50(2) 62-70.
22. Grant T, Soriano Y Fau - Marantz PR, Marantz Pr Fau - Nelson I, et al. Community-based screening for cardiovascular disease and diabetes using HbA1c. *Am J Prev Med* 2004; 26(4) 271-5.
23. Coppell KJ, Mann Ji Fau - Williams SM, Williams Sm Fau - Jo E, et al. Prevalence of diagnosed and undiagnosed diabetes and prediabetes in New Zealand: findings from the 2008/09 Adult Nutrition Survey. *N Z Med J* 2013; 126(1370):23-42.
24. Takahashi Y, Noda M Fau - Tsugane S, Tsugane S Fau - Kuzuya T, et al. Prevalence of diabetes estimated by plasma glucose criteria combined with standardized measurement of HbA1c among health checkup participants on Miyako Island, Japan. *Diabetes Care* 2000; 23(8): 1092-6.
25. d'Emden MC, Shaw Je Fau - Colman PG, Colman Pg Fau - Colagiuri S, et al. The role of HbA1c in the diagnosis of diabetes mellitus in Australia. *Med J Aust* 2012; 197(4):220-1.
26. Braatvedt GD, Cundy T Fau - Crooke M, Crooke M Fau - Florkowski C, et al. Understanding the new HbA1c units for the diagnosis of Type 2 diabetes. *N Z Med J* 2012; 125 (1362) 70-80.

1  
2  
3 27. Jeon JY, Ko S-H, Kwon H-S, et al. Prevalence of Diabetes and Prediabetes according to  
4 Fasting Plasma Glucose and HbA1c. *Diabetes Metabol J* 2013;37(5):349-57.  
5

6 28. Degeling C, Rock M Fau - Rogers WA, Rogers WA. Testing relationships: ethical arguments  
7 for screening for type 2 diabetes mellitus with HbA1c. *J Med Ethics* 2012; 38(3): 180-3.  
8

9 29. Nishtar S, Boerma T Fau - Amjad S, Amjad S Fau - Alam AY, et al. Pakistan's health  
10 system: performance and prospects after the 18th Constitutional Amendment. *Lancet* 2013;  
11 381(9884):2193-206.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Table 1 Characteristics of the participants by diabetes categories (n=18,856)

	Non-Diabetic N (%)	Pre-Diabetic N (%)	Diabetic N (%)	P-value
	13,598 (72.11)	2,057 (10.91)	3,201 (16.98)	
<b>Age (years)</b>				
20-30	2,772 (20.37)	218 (10.60)	176 (5.52)	<0.001
31-40	3,503 (25.74)	425 (20.66)	511 (16.01)	
41-50	3,802 (27.94)	654 (31.79)	1,033 (32.37)	
51-60	1,955 (14.37)	412 (20.03)	833 (26.10)	
61 & above	1,576 (11.58)	348 (16.92)	638 (19.99)	
<b>Gender</b>				
Male	7363 (54.15)	1099 (53.43)	1638 (51.17)	0.010
Female	6235 (45.85)	958 (46.57)	1563 (48.83)	
<b>Education</b>				
No formal education	9,853 (72.41)	1516 (73.70)	2,439 (76.43)	<0.001
Primary	1936 (14.23)	354 (17.21)	452 (14.16)	
Secondary	818 (6.01)	99 (4.81)	184 (5.77)	
Graduation	1001 (7.36)	88 (4.28)	116 (3.64)	
<b>Area</b>				
Urban	9,117 (67.00)	1,213 (58.97)	1,932 (60.55)	
Rural	4,491 (33.00)	844 (41.03)	1,259 (39.45)	<0.001
<b>Family History</b>				
Negative	10325 (75.93)	1210 (58.82)	1320 (41.24)	<0.001
Positive	3273 (24.07)	847 (41.18)	1881 (58.76)	
<b>Smoking</b>				
Never	12682 (93.26)	1893 (92.03)	2937 (91.75)	0.008
Ex-Smoker	275 (2.02)	49 (2.38)	91 (2.84)	
Current smoker	641 (4.71)	115 (5.59)	173 (5.40)	
<b>Systolic BP (mean ±SD)</b>	124.98	128.17	130.77	0.020
<b>Diastolic BP (mean ±SD)</b>	82.75	84.13	84.84	0.006
<b>BMI</b>				
Underweight (<18.5)	279 (2.05)	31 (1.51)	35 (1.09)	<0.001
Normal (18.5-<25)	5137 (37.78)	668 (32.47)	1019 (31.83)	
Overweight (25-<30)	5884 (43.27)	850 (41.32)	1288 (40.24)	
Obese1 (30-<35)	1844 (13.56)	396 (19.25)	621 (19.40)	
Obese 2 (35-<40)	372 (2.74)	83 (4.04)	178 (5.56)	
Obese 3 (≥40)	82 (0.60)	29 (1.41)	60 (1.87)	
<b>Waist circumference *</b>				
Normal Weight	6,787 (70.88)	645 (51.68)	1,142 (55.93)	<0.001
Over weight	1,676 (17.50)	285 (22.84)	357 (17.48)	
Obese	1,113 (11.62)	318 (25.48)	543 (26.59)	
<b>Waist to Hip ratio *</b>				

Normal Weight	3,219 (33.62)	394 (31.57)	658 (32.22)	
Over weight	5,528 (57.73)	768 (61.54)	1,171 (57.35)	
Obese	828 (8.65)	86 (6.89)	213 (10.43)	0.002

\* n for Waist circumference & waist to hip ratio is 12865

Table 2 Logistic regression analysis of the participant characteristics associated with having diabetes (HbA1c $\geq$ 6.5 % DCCT aligned /48 mmol/mol IFFC units) (n=18,856)

	Univariate OR (95% CI)	P-value	Multivariate OR (95% CI)	P-value
<b>Age</b>				
20-30	1		1	
31-40	2.21 (1.8, 2.6)	<0.001	2.03 (1.7, 2.4)	<0.001
41-50	3.93 (3.3,4.6)	<0.001	3.39 (2.9, 4.0)	<0.001
51-60	5.97 (5.0, 7.1)	<0.001	4.87 (4.1, 5.8)	<0.001
61 & above	5.63 (4.7, 6.7)	<0.001	4.93 (4.1, 6.0)	<0.001
<b>Gender</b>				
Male	1		1	
Female	1.12 (1.0,1.2)	0.003	1.04 (0.9, 1.1)	0.334
<b>Education</b>				
No formal education	2.02 (1.6,2.4)	<0.001	1.83 (1.5, 2.3)	<0.001
Primary	1.85 (1.49, 2.3)	<0.001	1.39 (1.1, 1.8)	0.006
Secondary	1.89 (1.47,2.4)	<0.001	1.57 (1.2, 2.0)	0.001
Graduation	1		1	
<b>Area</b>				
Urban	1		1	
Rural	1.26 (1.16, 1.34)	<0.001	1.08 (0.9, 1.2)	0.084
<b>Family History of diabetes</b>				
Negative	1		1	
Positive	3.98 (3.6,4.3)	<0.001	3.94 (3.6, 4.3)	<0.001
<b>Smoking</b>				
Never	1		1	
Ex- Smoker	1.39 (1.1, 1.8)	0.006	1.13 (0.9, 1.5)	0.323
Current Smoker	1.13 (0.9,1.3)	0.14	1.06(0.9, 1.3)	0.571
<b>Systolic BP</b>	1.02 (1.021, 1.026)	<0.001	1.01 (1.01, 1.02)	<0.001
<b>Diastolic BP</b>	1.01 (1.01, 1.02)	<0.001	0.99 (0.9, 1.0)	0.310
<b>BMI</b>				
Underweight (<18.5)	0.64 (0.4, 0.9)	0.001	0.71 (0.5, 1.0)	0.077
Normal (18.5-<25)	1		1	
Overweight (25-<30)	1.08 (0.9,1.2)	0.06	1.06 (0.9, 1.1)	0.182
Obese1 (30-<35)	1.57 (1.4,1.7)	<0.001	1.54 (1.3, 1.7)	<0.001
Obese 2 (35-<40)	2.22 (1.8,2.6)	<0.001	2.13 (1.7, 2.6)	<0.001
Obese 3 ( $\geq$ 40)	3.07 (2.2,4.2)	<0.001	2.44 (1.7, 3.5)	<0.001
<b>Waist circumference *</b>				

1					
2					
3	Normal Weight	1		1	
4	Over weight	1.18 (1.04, 1.34)	0.01	0.98 (0.8, 1.1)	0.774
5	Obese	2.46 (2.19, 2.77)	<0.001	1.86 (1.6, 2.2)	<0.001
6					
7	<b>Waist to Hip Ratio *</b>				
8	Normal Weight	1		1	
9	Over weight	1.02 (0.92, 1.13)	0.40	0.8 (0.7, 0.9)	<0.001
10	Obese	1.27 (1.07, 1.51)	0.005	1.13 (0.9, 1.4)	0.205
11					
12					

\* n for WC &WHR is 12865. The following variables were included in the multivariate regression: Age, gender, education, residence area, family history of diabetes, smoking, systolic and diastolic blood pressure and BMI.

For peer review only




Table 3: Summary statistics for diabetes diagnosed by HbA1c compared to diabetes diagnosed by 2hrs OGTT (n=1,027)

		[95% Confidence Interval]		
Prevalence	Pr (A)	40.6%	37.6%	43.7%
Sensitivity	Pr (+ A)	84.7%	80.8%	88.0%
Specificity	Pr (- N)	87.2%	84.3%	89.8%
ROC area	(Sens. + Spec.)/2	0.86	0.84	0.88
Likelihood ratio (+)	Pr (+ A)/Pr (+ N)	6.62	5.36	8.18
Likelihood ratio (-)	Pr (- A)/Pr (- N)	0.18	0.14	0.22
Odds ratio	LR (+)/LR (-)	37.62	26.34	53.73
Positive predictive value	Pr (A +)	81.9%	77.9%	85.4%
Negative predictive value	Pr (N -)	89.3%	86.5%	91.6%

Peer review only

1  
2  
3 Figure 1: Prevalence of diabetes (diagnosed by HbA1c $\geq$ 6.5 % DCCT aligned /48 mmol/mol  
4 IFFC units) by regions of Pakistan, age, gender, education, family history of diabetes,  
5 hypertension, waist circumference, waist to hip ratio and body mass index (n=18,856).  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only



Prevalence of diabetes (diagnosed by HbA1c≥6.5 % DCCT aligned /48 mmol/mol IFFC units)

246x187mm (300 x 300 DPI)

# Reporting checklist for cross sectional study.

Based on the STROBE cross sectional guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the STROBE cross sectional reporting guidelines, and cite them as:

von Elm E, Altman DG, Egger M, Pocock SJ, Gotsche PC, Vandembroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

		Reporting Item	Page Number
Title	#1a	Indicate the study's design with a commonly used term in the title or the abstract	1
Abstract	#1b	Provide in the abstract an informative and balanced summary of what was done and what was found	3
Background / rationale	#2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	#3	State specific objectives, including any prespecified hypotheses	5
Study design	#4	Present key elements of study design early in the paper	6
Setting	#5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6
Eligibility criteria	#6a	Give the eligibility criteria, and the sources and methods of selection of participants.	6-7

1		#7	Clearly define all outcomes, exposures, predictors, potential	7
2			confounders, and effect modifiers. Give diagnostic criteria, if	
3			applicable	
4				
5				
6	Data sources /	#8	For each variable of interest give sources of data and details of	7-8
7	measurement		methods of assessment (measurement). Describe	
8			comparability of assessment methods if there is more than one	
9			group. Give information separately for for exposed and	
10			unexposed groups if applicable.	
11				
12				
13				
14	Bias	#9	Describe any efforts to address potential sources of bias	8
15				
16				
17	Study size	#10	Explain how the study size was arrived at	6
18				
19	Quantitative	#11	Explain how quantitative variables were handled in the	7
20	variables		analyses. If applicable, describe which groupings were chosen,	
21			and why	
22				
23				
24	Statistical	#12a	Describe all statistical methods, including those used to control	8
25	methods		for confounding	
26				
27				
28		#12b	Describe any methods used to examine subgroups and	8
29			interactions	
30				
31				
32		#12c	Explain how missing data were addressed	8
33				
34				
35		#12d	If applicable, describe analytical methods taking account of	8
36			sampling strategy	
37				
38				
39		#12e	Describe any sensitivity analyses	8
40				
41	Participants	#13a	Report numbers of individuals at each stage of study—eg	8-9
42			numbers potentially eligible, examined for eligibility, confirmed	
43			eligible, included in the study, completing follow-up, and	
44			analysed. Give information separately for for exposed and	
45			unexposed groups if applicable.	
46				
47				
48				
49		#13b	Give reasons for non-participation at each stage	8
50				
51				
52		#13c	Consider use of a flow diagram	6
53				
54	Descriptive data	#14a	Give characteristics of study participants (eg demographic,	8-9
55			clinical, social) and information on exposures and potential	
56			confounders. Give information separately for exposed and	
57			unexposed groups if applicable.	
58				
59				
60				

1		#14b	Indicate number of participants with missing data for each	8-9
2			variable of interest	
3				
4				
5	Outcome data	#15	Report numbers of outcome events or summary measures.	9
6			Give information separately for exposed and unexposed	
7			groups if applicable.	
8				
9				
10	Main results	#16a	Give unadjusted estimates and, if applicable, confounder-	9
11			adjusted estimates and their precision (eg, 95% confidence	
12			interval). Make clear which confounders were adjusted for and	
13			why they were included	
14				
15				
16				
17		#16b	Report category boundaries when continuous variables were	9
18			categorized	
19				
20				
21		#16c	If relevant, consider translating estimates of relative risk into	9
22			absolute risk for a meaningful time period	
23				
24	Other analyses	#17	Report other analyses done—e.g., analyses of subgroups and	9
25			interactions, and sensitivity analyses	
26				
27				
28	Key results	#18	Summarise key results with reference to study objectives	9
29				
30				
31	Limitations	#19	Discuss limitations of the study, taking into account sources of	11
32			potential bias or imprecision. Discuss both direction and	
33			magnitude of any potential bias.	
34				
35				
36	Interpretation	#20	Give a cautious overall interpretation considering objectives,	11
37			limitations, multiplicity of analyses, results from similar studies,	
38			and other relevant evidence.	
39				
40				
41	Generalisability	#21	Discuss the generalisability (external validity) of the study	11
42			results	
43				
44				
45	Funding	#22	Give the source of funding and the role of the funders for the	12
46			present study and, if applicable, for the original study on which	
47			the present article is based	
48				
49				

50  
51 The STROBE checklist is distributed under the terms of the Creative Commons Attribution License  
52 CC-BY. This checklist was completed on 04. July 2018 using <http://www.goodreports.org/>, a tool  
53 made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)  
54  
55  
56  
57  
58  
59  
60